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General Introduction and aims of  the thesis
Heterotopic Ossification 
Heterotopic ossification (HO) is a fascinating phenomenon; fully differentiated bone 
forms in ectopic locations where bone is not normally present. This does not occur 
with any other specialized tissue. Bone tissue resulting from HO resembles normal 
lamellar bone. The pathophysiology of  HO is not fully understood. Trauma, however, 
appears to be the main etiological factor in HO (22). HO can occur following surgical 
trauma, burns, and neurologic injuries, but also in the context of  rare genetic disorders 
(42). Research into fibrodysplasia ossificans progressive, a rare heritable form of  HO, 
and progressive osseous heteroplasia, a developmental form, has provided insight into 
clinical, pathophysiological and genetic characteristics of  HO. Better understanding 
of  the complex developmental and molecular pathology of  these disorders may lead 
to more effective strategies to prevent and treat other, more common forms of  HO 
(41, 42).
The pathophysiology of  HO involves inductive signaling pathways, inducible 
osteoprogenitor cells, and an environment conductive to osteogenesis (14). After hip 
arthroplasty, the tissues surrounding the hip joint are at risk for developing HO, which 
is probably related to the presence of  osteoprogenitor cells in the wound bed. The 
local trauma probably triggers the inductive signalling pathway. Whether HO of  
body tissues occurs or not, may depend on a delicate balance between locally and 
systemically acting osteogenic and osteo-inhibitory factors (14).
HO after primary total hip arthroplasty (THA)
The reported incidence of  HO after THA varies between 10 and 90%, but the 
incidence of  clinically significant HO is considered to be much lower, i.e. between 
3 and 7 %( 1, 2, 28, and 60). HO is more prevalent among males (1, 3, 58, 60), 
and among patients with ankylosing spondylitis (1, 52), hypertrophic osteoarthritis 
(1, 52) and Morbus Forestier (52). The most powerful predictor is the occurrence of  
HO following previous THA of  the contralateral hip (47, 58, 60). More controversial 
factors that may contribute to the development of  HO include a lateral approach to 
the hip (8, 40), cemented prosthesis (21, 49, 56, 58) and high body weight (38).
In most cases, HO is merely a radiological finding without clinical consequences. In 
more severe cases, however, HO may result in reduced mobility of  the operated joint 
(2, 11, 23, 49, 64). Extensive bone formation may occur within three months, while full 
maturation of  bone takes up to one year (9).
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Several grading systems for HO following THA have been suggested (4, 11, 18, 19, 
79). In this thesis, the most commonly used grading system, the one described by 
Brooker (11), has been used. This grading system uses 5 classes (Figure 1).
	 Figure	1:	Brooker	classification
 0	 Isolated	bone	islands
 I	 Isolated	bone	islands
 II	 Bone	spurs	from	the	pelvis	or	proximal	femur,	
	 	 space	between	opposing	surfaces	>	1	cm
 III	 Bone	spurs	from	the	pelvis	or	proximal	femur,	
	 	 space	between	opposing	surface	<	1cm
 IV	 Apparent	bony	ankylosis
I II
III IV
0
mc 1>
mc 1<
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Prophylaxis of  HO 
Two different forms of  prophylaxis of  HO are being applied. The first is radiation 
therapy, which can be applied directly before or directly after the operation with similar 
results. After the first description of  prophylactic radiation therapy (16), 10 times 2 Gy, 
different dose regimen have been used. Dose regimen differ from 500 cGy to 800 cGy 
once, either pre- or postoperatively. The same cumulative dose can be administered in 
three to five fractions with similar effectiveness (5, 6, 27, 61, 62, 81).
The disadvantages of  radiation therapy are high costs, wound healing problems when 
irradiation is applied direct postoperatively and the risk of  secondary malignancies 
due to the irradiation. As radiation therapy is not available in all centers, the need 
for transferal to an other hospital for treatment in the direct postoperative phase is 
another disadvantage. 
The second mode of  prophylaxis is by non-steroidal anti-inflammatory drugs 
(NSAIDs). These drugs reduce the incidence of  HO. However, the main disadvantages 
are well-known gastrointestinal side effects, including gastric perforations ulcers and 
bleedings. 
Physiology of  Prostaglandins (PGs) 
In the 1930’s, von Euler (82) described the contraction of  smooth uterus muscle when 
seminal fluid was brought in contact with it. He attributed this phenomenon to a 
substance he called prostaglandin, since he thought it was produced by the prostate. In 
the 1960’s prostaglandins (PGs) were identified as a family of  related substances. 
PGs are formed from arachidonic acid by the enzyme cylooxygenase (COX). PGs 
play a central role in the inflammatory response to all kinds of  stimuli (54). When 
in 1980’s the two is-enzymes of  COX were discovered, the effects of  PGs could be 
clarified. In general, prostaglandins are needed for homeostasis and play a role in 
inflammation (54). For homeostasis PG is produced by the COX-1 pathway, in the 
context of  inflammation PG is formed by COX-2 (29). The discovery of  two different 
forms of  COX-blockers lead to better understanding of  the physiology of  PGs (29). In 
figure 2 the (simplified) COX-1 and COX-2 pathways are shown.
The constitutive isoform COX-1 leads to the formation of  PGI2 (Prostacyclin) which 
has vasodilator and anti-thrombogenic properties. In addition, it is cytoprotective 
when released by the gastric mucosa. COX-1 is also involved in the formation of  
thromboxane (TXA2) which is responsible for platelet function (54, 76). 
The inducible is form COX-2 is involved in the formation of  PGE2. PGE2 is found in 
synovial fluid of  arthritic joints and is the major PG involved in inflammation and pain 
(54, 83). Also fever is a typical PGE2 effect (76, 83).
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The effects of  PGE2 and PGI2 on the stomach are threefold. Firstly it reduces the 
secretion of  gastric acid, secondly intravenously PGE2 induces vasodilatation and 
thereby increases gastric mucosal blood flow and thirdly it stimulates the production 
of  gastric mucus (83).
PGE2 induces smooth muscle relaxation and thereby vasodilatation, which causes the 
erythema in acute inflammation. PGI2 also induces vasodilatation and its deficiency 
will lead to atherosclerosis and thrombosis (25). PGs have several functions in the 
kidney; most important are the diuretic and natriuretic effects (54, 55). PGs have been 
shown to increase osteoclast activity and subsequent bone resorption, and increase 
osteoblast activity and bone formation (36).
	 Figure	2:	COX-1	and	COX-2	pathways	
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Non steroidal anti inflammatory drugs (NSAIDs)
NSAIDs are a group of  drugs inhibiting the transformation of  arachidonic acid to 
prostaglandins by COX. COX is believed to be the rate-limiting enzyme in PG synthesis 
(73). This kind of  drugs is used in rheumatoid arthritis, but also for musculoskeletal 
pain and inflammation. This group of  drugs is the most commonly used painkiller, 
especially in musculoskeletal pain. With conventional NSAIDs, the isoforms COX-1 
and COX-2 are either inhibited to fairly the same extent, or COX-1 is inhibited more 
than COX-2 (7).
In table 1 examples of  traditional (non-selective) NSAIDs are given. 
	 Table	1:	examples	of 	traditional	NSAIDs
The desirable effects of  NSAIDs are analgesia and suppression of  inflammation. 
Appreciating the physiology of  PGs, several side effects of  these drugs can be 
expected. By blocking PG in the stomach, gastric acid production will increase, 
whereas mucus production will decrease. Theoretically, selective COX-2 blocking will 
result in less damage of  the gastric mucosa. In the cardiovascular system, NSAIDs 
will produce vasoconstriction. In the kidney, COX-2 is constitutively expressed and is 
regulated in response to alterations in intravascular volume. COX-2 metabolites have 
been implicated in mediation of  renin release, regulation of  sodium excretion and 
maintenance of  renal blood flow (15, 37).
Blocking the COX-1 pathway will also compromise the platelet function resulting in 
a prolonged bleeding time. The beneficial effect of  platelet function blocking is used 
to prevent myocardial infarction and stroke with aspirin.  Platelet function is expected 
to be preserved by selective blocking of  COX-2. This may result in a normal bleeding 
Generic name Brand name in the Netherlands
indomethacin Indocid
diclofenac Voltaren, Cataflam
ibuprofen Brufen
naprosyn Naprosyne, Aleve
nabumetone Mebutan
piroxicam Brexine
dexibuprofen Seractil
ketoprofen Oscorel, Orudis
tiaprofenic acid  Surgam
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Generic name Brand name in the Netherlands
meloxicam Movicox, Mobic
rofecoxib Vioxx 
celecoxib Celebrex
etodolac Not available in the Netherlands 
nimesulide Not available in the Netherlands
valdecoxib Bextra
parecoxib Dynastat
etoricoxib Arcoxia, Auxib
lumiracoxib Prexige
time as compared to the non-selective NSAIDs (29). However, in the cardiovascular 
system the combination of  vasoconstriction and unsuppressed platelet aggregation 
may lead to cardial ischemia (78). 
Animal and in vitro studies have demonstrated impaired bone healing in the presence 
of  traditional NSAIDs, as measured by a variety of  parameters (20, 36, 44, 45, 50, 
69, 80). More recent studies on the effects of  COX-2-selective inhibitors on bone 
healing have yielded similar results (34, 35, 73, 74). With mounting evidence that 
NSAIDs interfere with bone healing from these in vitro and animal studies, questions 
have arisen regarding the potential underlying mechanism, and whether these results 
can be translated into a clinical setting (36). Furthermore, in many studies COX-2 
knock-out animals have been used (43, 59, 66, 73, 84). However, the observations in 
these COX-2 knock out animals cannot automatically be translated into effects of  
pharmacological COX-2 blockade (33).
The rise and fall of  the COX-2 selective inhibitors
After the discovery of  the COX-2 iso-enzyme, pharmaceutical industries designed 
selective COX-2 inhibitors. The first two agents available for patients were rofecoxib 
and celecoxib. It turned out that some of  the traditional NSAIDs already on the market 
were preferential COX-2 inhibitors (7). In table 2 most used COX-2 preferential and 
selective NSAIDs are shown. 
	 Table	2:	examples	of 	COX-2	preferential	and	selective	NSAIDs
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The CLASS-study (72) (Celecoxib Long-term Arthritis Safety Study) in which 
Celecoxib was compared to Ibuprofen showed  less gastric ulcers in the celecoxib group 
and no difference in cardiovascular events between the groups. In the VIGOR-study 
(10) (Vioxx Gastrointestinal Outcomes Research) it was shown that in patients with 
rheumatoid arthritis, treatment with rofecoxib was associated with significantly fewer 
clinically important upper gastrointestinal events than treatment with naproxen, a 
nonselective inhibitor. Different studies comparing meloxicam with traditional NSAIDs 
showed fewer side effects especially in gastric perforations, ulcers and bleedings (29, 
75). As bone healing is also an inflammation induced process, there is concern to give 
patients with a fracture NSAIDs and especially COX-2 selective ones.
At therapeutic doses, neither celecoxib nor rofecoxib inhibited TXA2 synthesis by 
COX-1 in platelets, thus preserving intact aggregatory mechanisms unopposed by the 
antiaggregatory action of  PGI2 (7). 
On September 30 2004, Merck withdrew rofecoxib from the market because of  a 
higher incidence of  cardiovascular complications (71). The 3-year clinical trial called 
APPROVe (Adenomatous Polyp Prevention of  Vioxx), which was halted in late 
September (2 months before it was scheduled to end), was evaluating the efficacy 
of  rofecoxib in preventing the recurrence of  colorectal polyps among patients with 
a history of  colorectal adenomas. It revealed an increased relative risk for serious 
cardiovascular events, including heart attacks and strokes, beginning after 18 months 
of  treatment among patients taking rofecoxib that was about twice that of  patients 
taking placebo. The results for the first 18 months of  the study did not show any 
increased risk (71). 
This gave rise to worldwide discussions about the safety of  the COX-2 inhibitors. 
COX-1/COX-2 selectivity ratio is assessed in vitro; however, this value might be an 
over-simplification of  the in vivo actions of  these agents in humans. Discrepancies 
between in	vitro and in	vivo effects were attributed to several pharmacodynamic and 
pharmacokinetic mechanisms (29). The oversimplified COX-1/COX-2 ratio as a 
marketing tool on a high commercial value market might be misleading. 
The prophylactic effect of  NSAIDs on HO.
Dahl (17) was the first to describe the prophylactic effect of  the NSAID indomethacin 
on the incidence of  HO after hip arthroplasty. He observed that patients with 
rheumatoid arthritis developed less HO than osteoarthritis patients, and especially 
patients who received indomethacin developed less HO. In the 1970’s and 80’s many 
studies were performed to prove the prophylactic effect of  indomethacin on HO after 
THA (68). Initially the prophylaxis was given for six (13, 67), three and two weeks (39, 
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46, 53), all with similar results. Also other NSAIDs were tested for their prophylactic 
effects on HO and showed similar results (12, 24, 30-32, 65). Even a treatment period 
of  one week appears to be sufficient (57).
Gastric complications of  NSAIDs
It’s important to distinguish three different types of  gastric side effects: 
1.  symptoms: heartburn, pyrosis and nausea 
2.  endoscopic findings: gastric erosions and superficial ulcers 
3.  complications: perforation, ulceration and bleeding. 
These three complications can occur independently, as explained in the next 
paragraph. Approximately 30% of  all patients on traditional NSAIDs suffer from 
gastrointestinal side effects; among patients over 65, the incidence of  these side effects 
is estimated at 40% (26). In many studies, as many as 25% of  patients needed to cease 
the treatment due to side effects (13, 24, 28, 30, 63, 70). However, in the placebo-
group a comparable number of  patients had to stop due to side effects as well (13, 24, 
28, 30, 63, 70). Heartburn, gastric pain and/or dyspepsia may occur in up to 60% 
of  patients taking NSAIDs, but there is no clear correlation between symptoms, or 
endoscopic findings and complications (51). On the other hand 80% of  patients who 
developed a perforation, ulcer or bleeding, lacked a history of  gastric complaints or 
preceding symptoms before this event (29). 
Although predictors of  gastric side effects have been identified, including age and 
history of  ulcer complications, there is no understanding of  what separates the 
large majority of  subjects who tolerate NSAIDs well from those who develop ulcer 
complications (77). Several studies, particularly those on aspirin, have indicated that 
acute damage (of  the gastric mucosa) is much more widespread than damage observed 
after several days or weeks (77). The annual incidence of  NSAID-related clinical upper 
gastro-intestinal events (complicated and symptomatic ulcers) is approximately 2.5% to 
4.5%, and that of  serious complications (severe bleeding, perforation, and obstruction) 
about 1% to 4 % ( 48, 77).  Therefore, with short term use of  NSAID (<1 week) we 
expect the side effects of  NSAID to be limited to mainly symptoms and superficial 
erosions. With a prolonged use of  NSAIDs the prostaglandin synthesis inhibition can 
give a reduced blood flow in the gastric mucosa and a small ulcer can become larger 
and symptomatic (43). Although gastro protection is COX-1 mediated, the repair 
of  gastric mucosal damage is COX-2 mediated so also with COX-2 inhibition the 
healing potential of  the gastric mucosa is impaired (77).
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Outline and Aims of  this Thesis
The prophylactic effect of  traditional NSAIDs on the incidence of  HO after primary 
total hip arthroplasty (THA) is well established, but gastro-intestinal side effects are 
frequently observed. The aim of  our studies was to investigate alternative treatment 
strategies to diminish these side-effects. In chapter 2 the standard treatment period of  
one week with indomethacin is compared with a three days regimen. In chapter 3, 5 
and 6 the prophylactic effects of  COX-2 preferential and selective NSAIDs on HO 
as compared to the standard treatment with indomethacin is described. In chapter 
4 the perioperative blood loss after THA following treatment with indomethacin 
versus meloxicam is compared. Because there is rising awareness of  the negative effect 
of  NSAIDs on fracture healing and graft incorporation, a study was conducted to 
compare the effect of  different NSAIDs on bone ingrowth in titanium bone chambers 
in goats. Chapter 7 is based on this study.
As HO is believed to be related to the local tissue trauma, the profiling of  cytokine in 
the surgical wound after THA could add to the understanding of  the inflammatory 
mechanisms underlying HO. In chapter 8 we describe a study on cytokine concentration 
in drain fluid after THA.
The following research questions were formulated:
1  Can the duration of  treatment with indomethacin to prevent HO after THA 
 be shortened?
2  Are the prophylactic effects of  COX-2 selective NSAIDs on the development 
 of  HO after THA similar to that of  indomethacin?
3  Do Non-Steroidal Anti-Inflammatory Drugs impair bone ingrowth?
4  Is it possible to measure the local inflammatory response after THA by means 
 of  cytokine levels at the site of  surgery?
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Abstract
Although indomethacin is effective in preventing heterotopic ossification (HO) after 
total hip arthroplasty when used for 8-14 days, side-effects are frequently observed. We 
carried out a prospective, non-randomized pilot study of  prophylaxis for heterotopic 
ossification (HO) in total hip arthroplasty using indomethacin for 3 days to prevent 
heterotopic ossification. We used a two-stage design for phase 2 clinical data, based on 
earlier studies in our department. 
Our study-group consisted of  nineteen patients of  which 14 (74 %) developed HO; 
seven (37 %) showed grade I, four (21 %) grade II and three (15,8%) grade III according 
to the Brooker classification.
We compared these results with two historic control groups, one receiving indomethacin 
for seven days, the other group received no prophylaxis. We did not see any reduction 
of  the ossification relative to the group which received no prophylaxis. Indomethacin 
for three days seems not to be sufficient to prevent heterotopic ossification.
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Introduction
Heterotopic ossification is a frequent complication of  total hip arthroplasty. To prevent 
heterotopic ossification low dose radiation therapy (5, 18) or non-steroidal anti-
inflammatory drugs (NSAID) can be used. Initially, effective prophylaxis by NSAIDs 
was obtained by medication periods of  4 to 6 weeks. Re cent ly, studies were presented 
that NSAIDs are also effec tive after treatment periods of  5 to 14 days (7, 9, 10, 12, 
and 14).
At our department Hu et al  (H.P.Hu, C.Th.Koorevaar,  J.A.M. Lemmens, T.J.J.H. 
Slooff, unpublished data, 1996) showed also the effective prevention of  heterotopic 
ossification by 7 days indomethacin. However, even in a 7 day treatment the high 
amount of  side-effects caused by indomethacin is a serious clinical problem.  The 
purpose of  this prospective study with indome thacin for 3 days was to deter mine if  
this short treat ment regime can prevent heteroto pic ossification. 
Patients and methods
This study was started after approval by the local ethics committee. We used a two-
stage study design for phase 2 clinical trials (23). For calculation of  the number of  
cases needed in this study we used the data of  a patient-group of  our department 
who did not receive any prophylaxis (17), and data obtained at our department of  a 
patient group who received 7 days indomethacin (H.P.Hu, C.Th.Koorevaar, J.A.M. 
Lemmens, T.J.J.H.Slooff, unpublished data, 1996) (table 1). Given these data a 3 
days regime of  indomethacin is considered only effective if  at least 80 % of  the cases 
will have a Brooker (3) classification 0, 1 or 2. In the two-stage design, an effectivity 
smaller than 80 % is not recommended (reject with α = 0,05). On the other hand, an 
effectivity of  at least 95 % needs to be detected with a high probability (≥90 %). For 
the first phase of  this study design 19 cases were necessa ry. If  these criteria had been 
fulfilled the second phase is started for another 23 patients.
Between September 1996 and January 1997 all consecutive patients with osteoarthritis, 
who were listed for a cemented total hip arthroplasty, were selected for this study. 
Three patients refused to enter the study. One case was excluded because of  renal 
insufficiency. Two cases were lost due to accidentally given NSAIDs after the 3 
day indomethacin scheme. 19 cases were entered in the study, all signed informed 
consent.
Diagnosis was primary osteoarthritis in 13 cases and secondary osteoarthritis in 6 
cases, due to avascular necrosis (3) and congenital hip dysplasia (3). There were 13 
women and 6 men; the average age of  the group was 62,5 years (25 to 81 years). 
All patients stopped non-steroidal anti-inflammatory drugs 10 days before operation. 
Paracetamol was allowed.
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In all patients a posterolateral approach without trochanteric osteotomy was used and 
a cemented Charnley hip prosthesis was inserted. The patients received antibiotic 
prophylaxis during operation (Cefazolin 1 gram intravenous.) Thromboembolic 
prophylaxis was established by low molecular heparin (nadroparin 10.000 IE a day, 
subcutaneous) during the first days and followed by acenocoumarol orally for three 
months. In all patients a redon-drain was utilised for two days. Three days after surgery 
full weight bearing was allowed, with use of  two crutches. 
Patients received immediately after operation a suppository of  100 mg indomethacin. 
Afterwards they continued for three days with Indomethacin three times daily 50 mg 
orally as a tablet. Side-effects were daily recorded up to 7 days. No NSAIDs were 
permitted thereafter, if  necessary pain was relieved by paracetamol.
Clinical and radiographic examinations were performed after five days, six weeks and 
six months post-operatively. Conventional anteroposterior pelvic radiographs were 
assessed. The classification of  heterotopic ossification by Brooker (3) was used (table 
2). The radiographs were evaluated by three of  the authors (H.v.d.H., W.S., and A.L.) 
on a consensus base.
	 Table	1:	Heterotopic	ossification	after	primary	total	hip	arthroplasty	
	 with	different	prophylaxis
Brooker  No Indomethacin   Indomethacin 
grade prophylaxis 7 days 3 days
 N=170 N= 99  N=19
0 40 (24%) 72 (73%) 5 (26%)
1 33 (19%) 24 (24%) 7 (37%)
2 48 (28%) 1 (1%) 4 (21%)
3 29 (17%) 1 (1%) 3 (16%)
4 20 (12%)  1 (1%)  -
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	 Table	2:	Classification	of 	heterotopic	ossification	by	Brooker
Results
No major com plication was seen due to indomethacin, although some had faint ga stro-
intestinal complaints especially on the first post-opera tive day. All patients completed 
the 3 day protocol.
After 6 months 14 cases (73,7 %) showed heterotopic ossificati on (table 1). Wide-spread 
ossification grade 3 was present in 3 of  these cases (15,8 %). One of  these 3 cases 
had clinical signs with pain and reduced function, and is planned for re-operation to 
remove the ossifications.  
These data were entered in the phase 2 study design. We hypothesized in this study 
that the effectiveness of  indomethacin should be at least 80 % (α = 5 %, β = 90 %). 
The obtained data did not fulfill these criteria. Therefore, 3 days indomethacin was 
not effective enough for preventing heterotopic ossification using these criteria. We did 
not start the second phase of  the study. 
Discussion
The prophylactic effect of  NSAIDs on heterotopic ossification was first observed 
by Dahl (6) using indomethacin as analgesic after THA. Several other studies have 
proven the prevention of  heterotopic ossification with indomethacin (4, 13, 15, 20-22, 
24). Initially, prophylactic treatment was used for months. Several studies (4, 20-22) 
showed that indomethacin was highly potent in preventing heterotopic ossification 
after total hip replacement when using indomethacin for 6 weeks after operation. 
Later Sodemann et al (24) showed the same effect with indomethacin or ibuprofen 
given for three weeks. Recent studies show similar re sults with short term treatment 
periods. Kjærsgaard-Andersen et al(12, 14), McMahon et al(19), Wurnig et al(27), 
Amstutz et al(2) and Dorn et al(7) showed the prophylactic effect when using indo-
methacin for 8 to 14 days. 
Grade Bone formation
I Isolated bone islands
II Bone spurs from the pelvis or proximal femur, 
 space between opposing surfaces > 1 cm
III Bone spurs from the pelvis or proximal femur, 
 space between opposing surface < 1cm
IV Apparent bony ankylosis
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Because of  side-effects due to indomethacin several other NSAIDs have been studied. 
Gebuhr (9-11) showed the effect of  naproxen for 4 weeks and 8 days and tenoxicam for 
5 days. Wahlström (25, 26) showed the effect of  diclofenac used for 6 weeks. Elmstedt 
et al (8) and Sodemann et al (24) showed the effect of  ibuprofen, when given for three 
months or three weeks respectively. However, Ahrengart et al (1) showed that there 
is no effect of  ibuprofen for 10 days on the incidence of  ossification. Kjærsgaard-
Andersen et al (14) showed that aspirin for six weeks is effective. 
At our departments Hu et al. (H.P.Hu, C.Th.Koorevaar, J.A.M. Lemmens, T.J.J.H. 
Slooff, unpublished data, 1996) showed in a retrospective study the effectiveness of  a 
7 day treatment with indomethacin. The obtained data are comparable to the results 
of  6 weeks indomethacin or 10 days indomethacin (14, 22). Recently Knelles et al 
(16) showed in a prospective, randomized study the same results with indomethacin 
for 7 days, but was not able to confirm the good results with aspirin published by 
Kjærsgaard-Andersen et al (14). 
Although indomethacin is a very powerful drug to prevent heterotopic ossification, 
the high incidence of  side-effects and possible interference with anticoagulation 
prophylaxis is, even in a 7 day treatment, a problem. Knelles (16) showed 22 % side 
effects and in 2,2 % sufficient to warrant withdrawal. Cella et al (4) revealed that 
19 % had contraindications to indomethacin and 18 % were withdrawn from the 
drug during the study. Therefore, we started this study to evaluate the ability of  a three 
day course of  indomethacin to prevent heterotopic ossification after THA. Given the 
effectiveness of  NSAIDs from literature and from our own experience, in our view it 
was not acceptable from an ethical point of  view to start a placebo controlled study 
design.
The data were entered in the two stage study design using as reference historical patient 
data (H.P.Hu, C.Th.Koorevaar, J.A.M. Lemmens, T.J.J.H.Slooff, unpublished data, 
1996) (17) from our department. These data are comparable with other published 
studies. In all our studies patients were operated on using a posterolateral approach 
and a cemented total hip was inserted. The same radiologist (A.L.) was involved in all 
studies.
Using this two-stage study design, we concluded, although 3 days indomethacin may 
have some effect in preventing heterotopic ossification, that the results are inferior 
relative to the 7 day period. We confirm the observation of  the recent study of  Dorn 
et al (7) using a 4 day scheme. We conclude that very short treatment periods with 
indomethacin are not effective enough in preventing heterotopic ossification. We 
continue the 7 day treatment with Indomethacin.
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Abstract
Methods: A prospective, cohort study for prophylaxis of  heterotopic ossification 
(HO) in primary total hip arthroplasty of  Indomethacin (n=89) versus Meloxicam 
(n-92) for 7 days was conducted. To assess the interobserver variability of  the Brooker 
classification, all radiographs were evaluated by three investigators. 
Results: In the Indomethacin group 25 patients developed HO; 22 grade I, two 
grade III and one grade IV.  In the Meloxicam group 34 developed HO; 30 grade I, 
one grade II and three grade III according to the Brooker classification. 
Conclusions: We were not able to show any difference between Indomethacin and 
Meloxicam in preventing heterotopic ossification after primary hip arthroplasty. We 
found a high interobserver variability in the grading system according to Brooker, in 
particular for the higher grades.
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Introduction
Heterotopic ossification (HO) is frequently observed after primary total hip arthroplasty. 
HO has been related to the extent of  tissue trauma (16), to previous hip surgery (1, 26), 
HO on the contralateral hip (19, 33, 41), and epidural anesthesia (16). The incidence 
is higher after an anterolateral approach compared to a posterior approach (5), and 
is higher after a transtrochanteric compared to a direct lateral approach (42) or a 
posterolateral approach (6). Men are more frequently affected (1, 26, 33, 45). There 
is no agreement in the literature as to whether there is difference between cemented 
and uncemented THA. Some studies show no difference (5, 35, and 47), Lieberman et 
al (25) found more HO after cemented THA in osteoarthritis, Maloney et al. found a 
higher incidence in uncemented THA (28). Pulsed lavage does not affect the incidence 
of  HO (40). Although HO might reduce range of  motion, usually it does not alter hip 
function or produce pain (1, 3) except for Brooker grades 3 to 4. Patient satisfaction has 
been reported to decrease from 90% good or excellent in patients without HO to 30% 
good or excellent in the higher grades (12).  To prevent heterotopic ossification, low 
dose radiation therapy (20, 21, 27, 39, 44) or non-steroidal anti-inflammatory drugs 
(NSAID) may be used (31, 32). The prophylactic effect of  NSAIDs for heterotopic 
ossification was first observed by Dahl (8) who used Indomethacin as analgesic after 
THA. Several other studies have illustrated the ability of  Indomethacin to prevent 
heterotopic ossification. Initially, prophylactic treatment was used for months. More 
recent studies show similar re sults with treatment periods ranging from 7 days to 6 
weeks (4, 7, 17, 18, 20, 29-31, 36, 37, 49). Indomethacin used for three (43) or four 
(11) days showed inferior results. The frequency of  side effects of  Indomethacin cause 
a serious clinical problem, even with a 7-day treatment (7). 
The purpose of  the present study was to deter mine if  a selective COX-2 inhibitor 
would show the same decrease in HO with fewer side effects as compared to 
Indomethacin. The second aim was to evaluate the interobserver variability of  the 
Brooker classification.
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Patients and methods
This study was started after approval by the local ethics committee. Between January 
1999 and July 2001, all consecutive patients with osteoarthritis, who were scheduled for 
a primary total hip arthroplasty, were eligible to participate in this study. Inclusion was 
performed by the anesthesiologist, randomization by the department of  orthopedic 
research. The inclusion and exclusion criteria are listed in Table 1.
 Table 1: inclusion and exclusion criteria
	 Table	2:	classification	according	to	Brooker
A total of  199 patients entered the study, but 18 were excluded: one patient appeared 
not to have signed the informed consent, three patients did not have their operation, 
five patients failed to receive their prophylaxis and finally the medication was stopped 
after 2 to 4 days in1 patient in the Indomethacin group due to the side effects and in 8 
patients for unknown reasons (2 in the Indomethacin- and 6 in the Meloxicam-group) 
the reason was not mentioned in the medical record).
Inclusion criteria Exclusion criteria
Primary THA Previous surgery on the same hip
Spinal or epidural  Included in another study
anaesthesia
Able to sign informed  History of  bleeding disorder
consent
Age 18-85 years History of  gastric ulcer
 Rheumatoid arthritis
Grade Bone formation
I Isolated bone islands
II Bone spurs from the pelvis or proximal femur, 
 space between opposing surfaces > 1 cm
III Bone spurs from the pelvis or proximal femur, 
 space between opposing surface < 1cm
IV Apparent bony ankylosis
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There were 124 women and 57 men, mean age 67 years (range 42 to 87 years).  Of  
the 181 patients in this study, 86 underwent an uncemented, 37 an cemented and 
58 a hybrid prosthesis (table 5). Non-steroidal anti-inflammatory drugs were stopped 
10 days before surgery. Paraceta mol was allowed. At the day of  surgery, all patients 
received 7.5 mg midazolam orally one hour before spinal anesthesia. Spinal anesthesia 
was performed in each of  these patients by administering 20 mg bupivacain and 0.1 
mg morphine dissolved in 4 ml saline.
In all patients a standard posterolateral approach without trochanteric osteotomy was 
used. All patients received antibiotic prophylaxis (A single intravenous admistration 
of  1 gram of  Cefazolin) Thromboembolic prophylaxis consisted in subcutaneous 
administration of  low molecular heparin (nadroparin 10.000 IE once a day) during 
the first days and continued with acenocoumarol orally for three months. All patients 
had a vacuum drain for one or two days. Three days after surgery full weight bearing 
was allowed. 
The Indomethacin group received a suppository of  100 mg Indomethacin one hour 
before surgery; and three oral doses of  50 mg the next seven days. The meloxicam 
group received a suppository of  15 mg one hour before surgery, followed by 15 mg 
Meloxicam once a day for seven days. No NSAIDs were permitted after this treatment 
period, if  necessary pain was relieved by paracetamol or morphine. Despite the 
protocol 89 patients received their prophylaxes only for 5 or 6 days (Indomethacin 
group 19 and Meloxicam group 70). Nineteen patients received NSAIDs for 8 to 15 
days (Indomethacin group 16, Meloxicam group 3).
Conventional anteroposterior pelvic radiographs were made five days after surgery, 
after six weeks, and after six months using the classification of  heterotopic ossification 
by Brooker (Table 2). To investigate the interobserver variability of  this classification 
system, 195 radiographs were independently evaluated by three investigators (H.v.d.H., 
M.S., and N.K.). To reach a consensus on radiographs with different observer scores 
the three investigators met in a joint reading. Radiographs with different observer 
scores were again classified with the three investigators together to reach a consensus. 
This study was not blinded, but the investigators who classified the X-rays were 
blinded concerning the prophylaxis the patients had received. After the radiographs 
had been scored, the medical records were consulted to determine which medication 
each patient had received and to control the length of  the treatment.
The two groups were compared using the chi-square test, with α set at 0.05.
Furthermore we compared these groups with a historic control group, in which 
the patients did not receive any prophylaxis.  In all patients in this control group 
also a posterolateral approach without a trochanteric osteotomy was used and the 
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patients had the same demographics and inclusion criteria. This group consisted of  
170 patients and has been described by Lemmens (24). In this historic control group 
76% developed HO (19% grade 1, 28% grade 2, 17% grade 3 and 12% grade 4). 
We considered a placebo controlled study design unethical taking into account the 
effectiveness of  NSAIDs reported in the literature (20, 31).
The interobserver variability was tested by an agreement analysis giving the weighted 
Cohen’s kappa as measures of  inter-rater agreement.
Results 
The results of  the classification according to Brooker are shown in table 3 and 4. In 
74% (n=146) all observers assigned the HO to the same Brooker grade, but for most 
grades two to four the scores were not equivalent.
	 Table	3	Inter-observer	variability	between	different	grades	of 	ossification
	 Cases	in	which	all	investigators	classified	the	radiographs	to	the	same	
	 Brooker	classification,	or	in	which	there	was	lack	of 	agreement	(n=195)
	 Table	4	Interobserver	variability	between	different	investigators
	 The	weighted	kappa	values	for	the	different	observers,	95%	confidence	interval	between		
	 brackets.	OS	=	Orthopedic	Surgeon,	OR=	Orthopedic	Resident,	R	=	Radiologist.
Brooker class  Agreement(n=145) Lack of  agreement (n=50)
Grade 0 115 14
Grade 1 28 29
Grade 2 1
Grade 3 1 6
Grade 4  1
 Brooker grade 0 or 1 Grade 2,3 or 4
OS versus OR 0,66 (0,53-0,80) 0,38 (0,05-0,69)
OS versus R 0,70 (0,57-0,82) 0,64 (0,43-0,85)
OR versus R 0,58 (0,44-0,72) 0,74 (0,50-0,97)
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After 6 months, 59 cases (33%) showed heterotopic ossificati on. High ossification 
grades 3 or 4 were present in 6 of  these cases (3%). The results for the different groups 
are shown in Table 5.
Although most patients in the Meloxicam group received their prophylaxis for only 5 
days, we did not observe a difference (p=0.11) between the Indomethacin group and 
the Meloxicam group. However, the difference was statistically significant between the 
historic control group, in which the patients did not receive any prophylaxis against 
heterotopic ossification, and both the Indomethacin and the Meloxicam group (for 
both groups p< 0.001) (Figure 1).
Looking at the length of  treatment in both experimental groups combined we found 
a significant difference (p=0.01) between those who received their prophylaxis for five 
or six days, and those received 7 days or more. In 9 patients (excluded from the study: 
see patients and methods) the medication was stopped after 2 to 4 days: in 1 patient in 
the indomethacin group due to side effects and in 8 patients for unknown reasons (2 
in the indomethacin and 6 in the meloxicam group) Two of  these patients developed 
grade 3 HO, one in each group. No difference was found for cemented or uncemented 
THA. Although the observed prevalence of  HO was higher in men, this difference 
was not significant.
	 Figure	1	The	incidence	of 	heterotopic	ossification
	 The	first	bar	represents	the	historic	control	group	not	receiving	any	prophylaxis	(24),	
	 the	second	and	third	represent	the	results	of 	this	study.
100%
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70%
60%
50%
40%
30%
20%
10%
0%
no prophylaxis indomethacin
medication
meloxicam
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Complications
One patient had a massive bleeding from a gastric ulcer on the seventh day after 
starting Indomethacin, and was treated with endoscopic sclerotherapy and received 7 
units of  red blood cells. In two patients, one in each group, a gastric ulcer perforated 
and laparotomy and closure of  the perforation were performed. Both patients were 
H. Pylori negative.
In 16 patients the wound drained for more than a week without signs of  infection (6 in 
the Meloxicam group, 10 in the Indomethacin group). One was treated surgically; the 
others were treated conservatively and received continued prophylactic antibiotics.
One patient had a superficial wound infection, which was treated with antibiotics. 
Three patients had a deep infection; one was treated with antibiotics, one with a one-
stage revision and one prosthesis needed to be removed.
	 Table	5:	heterotopic	ossification	after	primary	total	hip	arthroplasty
	 Type	of 	prothesis:	U=uncemented;	C=	cemented;	H=hybrid.
	 Treatment	group:	I	=	Indomethacin;	M	=	Meloxicam
	 Number:	M	=	male;	F	=	female.
Discussion
This study evaluates the effect of  the selective COX-2 inhibitor Meloxicam versus 
Indomethacin to prevent heterotopic ossification after primary THA. We could not 
detect a difference between the two treatments. When comparing the results with 
a historic control group the difference between both experimental groups and the 
historic control group (no treatment) is significant (24). 
We considered a placebo controlled study design unethical taking into account the 
effectiveness of  NSAIDs reported in the literature (20, 31) 
 I  M I M I  M
 (total group) (total group) (5-6 days) (5-6days) (≥7 days) (≥7 days)
Number  89 92 19 70 70 22
(M/F) (33/56) (22/70) (8/11)  (10/60) (15/55) (4/18)
Type (U/C/H) 37/21/31 49/16/27 8/3/8 35/13/22 32/15/23 11/3/6
Grade 0 64 58 8 41 56 15
Grade 1 22 30 9 26 13 4
Grade 2  1
Grade 3 2 3 1 2 1 1
Grade 4 1  1
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Given the results of  this study, with comparable results in preventing HO (31), and 
fewer side-effects with the selective COX-2 inhibitor, the HO prophylaxis in our clinic 
has now been changed from indomethacin  50 mg 3 times daily to meloxicam 15 mg 
once daily for seven days. 
Kristensen et al (23) found increased perioperative blood loss after the use of  
indomethacin, due to the reduction in platelet aggregation. In a subgroup of  our study 
group Weber et al. (46) found a decrease in per- and postoperative blood loss of  15% 
in the meloxicam group compared to the indomethacin group. 
Although indomethacin is a powerful drug to prevent heterotopic ossification, the 
high incidence of  side effects (31) poses a clinical problem. Knelles (20) showed 22% 
side effects which resulted in study withdrawal of  2,2 %.  Cella et al (7) revealed 
contraindications to indomethacin in 19% of  patients, and one third of  their 
patients were withdrawn from their study. It seems the treatment period of  one week 
with indomethacin is the shortest effective period (43). Because of  the side effects 
accompanying indomethacin several other NSAIDs have been studied. Naproxen for 
8 days or 4 weeks (13, 14), or tenoxicam for 5 days and 6 weeks (6), have the same 
prophylactic effect as indomethacin, ibuprofen used for 5 (22) or 10 (2) days shows less 
favorable results, but after three weeks of  ibuprofen the effect is comparable to that of  
indomethacin(34, 41).
In recent years COX-2 selective inhibitors have been developed, with less side-effects 
and the same pain reducing effects (9, 10, 15, and 38).
In our study we found a 74% agreement and a weighted kappa ranging from 0.58 to 
0.70 for grade 0 and 1 and from 0.38 to 0.74 for grade 2,3 or 4. In general kappa values 
between 0.4 and 0.7 are considered to show a fair to good interobserver reliability.
To our knowledge the only study describing the reliability and validity of  the Brooker 
classification shows 68% agreement and a weighted kappa of  0.57 (48). That study 
based on 77 radiographs does not give the prevalence of  HO; furthermore no 
distinction is made between the inconsistencies between the different grades. 
Although the Brooker-classification has been used in most studies, we found a high 
interobserver variability, particularly for the high grades, but also in some grade 0 and 
grade 1 cases with very small bone islands around the greater trochanter. Even small 
pieces of  bone in the greater trochanter region on the radiograph six months after 
surgery, which were not present on the direct postoperative radiograph, were scored 
as grade 1. In the six radiographs showing grade three and four ossification, the three 
observers all agreed there was a significant ossification, but there was no agreement on 
the presence of  a bony ankylosis. 
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Conclusions
Although we found no difference between the meloxicam group and the indomethacin 
group in preventing HO, this study lacks the power to show that the results of  the two 
different prophylaxes are the same. When we want to show that both treatments are the 
same we would have needed 1621 patients (with alpha is 5% and beta is 20%).  When 
comparing the results with a historic control group, which did not receive prophylaxis 
for HO, the difference for both treatments is significant, even though the majority 
of  the patients in the meloxicam group received their prophylaxis for only five days. 
Because of  the fewer side effects shown in other studies and comparable results in 
preventing HO, the HO prophylaxis in our clinic will be changed from indomethacin 
3 times daily 50 mg to meloxicam 15 mg once daily for seven days.
Although we found a high interobserver variability in the grading system according 
to Brooker especially for grade two to four, these kappa values are still considered to 
show a good reliability. 
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NSAIDs and perioperative blood loss in hip surgery
Abstract
Background: In this prospective randomized study we tested the hypothesis that use 
of  more cylooxygenase 2 (COX 2)-selective non-steroidal anti-inflammatory drugs 
(NSAIDs) can reduce perioperative blood loss com pared with non-selective NSAIDs.
Methods: Data from 200 patients who underwent total hip replacement were studied. 
Two NSAIDs were compared: indomethacin 50 mg (n = 82) and meloxicam 15 mg (n 
= 86). Both NSAIDs were given orally 1 h before surgery.
Results: The two groups were not different with respect to age, gender, ASA class or 
duration of  surgery. When indomethacin was used preoperatively, intraoperative blood 
loss was 623 ± 243 mL (mean ± SD) and postoperative blood loss 410 ± 340 mL. After 
meloxicam, these values were 524 ± 304 mL and 358 ± 272 mL, respectively. Total 
perioperative blood loss after meloxicam was 17% (P < 0.05) less than that observed 
after indomethacin.
Conclusion: Perioperative blood loss after meloxicam is less than after indomethacin. 
These in vivo findings are consistent with in vitro results using selective COX 2 
NSAIDs.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are used in the perioperative period 
for analgesia and reduction of  edema in the surgical field. However, they exhibit several 
side-effects: reduction of  renal blood flow, an increased incidence of  gastric com plaints 
and increased blood loss during surgery. These adverse effects result from inhibition of  
the physio logical formation by cylooxygenase (COX) 1 of  sev eral prostanoids: PGE2 
and PGI2 with a cytoprotective function, and thromboxane A2, which is responsible for 
platelet aggregation. In contrast, newer COX 2- selective NSAIDs, such as meloxicam, 
are considered to influence only the inflammatory response (edema, pain and fever). 
Our hypothesis was that this selec tivity of  action can be extrapolated to clinical prac-
tice, and that administration of  a COX 2-selective NSAID would result in decreased 
perioperative blood loss compared with administration of  a non-selective compound. 
To test this hypothesis, we performed a randomized study in patients undergoing 
total hip replacement, and compared perioperative blood loss after use of  one of  two 
NSAIDs: indomethacin and meloxicam.
Methods
The study was approved by the Ethical Committee of  our Hospital. Patients (ASA 
I–III) scheduled for total hip surgery using intrathecal anaesthesia were poten tially 
eligible for the study. Patients with a history of  peptic ulcer disease, renal dysfunction 
or allergy to any NSAID were excluded. The remaining patients were randomized 
to one of  two groups: those receiving meloxicam 15 mg orally, once a day, or those 
receiv ing indomethacin 50 mg orally, three times a day. The study was not masked. 
Patients were asked to stop use of  any NSAID 2 weeks prior to surgery. In case of  
severe pain acetaminophen (paracetamol) was avail able if  necessary. Patients who 
failed to stop the use of  NSAIDs were excluded.
All patients were premedicated with midazolam 7.5 mg orally 1 h before administration 
of  intrathecal anaesthesia; at the same time the first dose of  NSAID was given. 
Intrathecal anaesthesia (27-G pencil point needle) was administered using bupivacaine 
20 mg plus morphine 0.1 mg to a total volume of  4 mL. The anaesthesiologist 
administered midazolam (1 mg at intervals of  not less than 5 min) until the patient 
indicated that adequate sedation was achieved. Fluid replacement was by protocol: 
glucose 500 mL 2.5%/ NaCl 0.9% solution was administered after placement of  an 
intravenous cannula before starting surgery. The same solution was infused during 
surgery at 250 mL/h, and after surgery at 100 mL/h. A col loid solution (Gelofusine®) 
was administered to match measured blood loss (see below), with a maximum of  2.5 
L per 24 h. Non-invasive arterial pressure, heart rate (electrocardiogram), oxygen 
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saturation (SpO2), and respiratory frequency were continuously moni tored during 
anaesthesia and in the intensive care unit (ICU) during the first 24 h after surgery.
Blood loss
One day before surgery, patients received acenocou marol 3 mg. Intraoperative blood 
loss was measured by operating nurses unaware of  the NSAID given. Total blood loss 
was calculated by taking into account the volume in the suction containers, the weight 
of  the surgical sponges, and the irrigation fluid used. In the postoperative phase all 
patients remained in an ICU for 24 h, which is our normal policy. The volume of  
blood in a high vacuum wound drainage system was collected and measured for 24 h 
after surgery.
Pain
In the postoperative period, all patients were treated with indomethacin 50 mg orally, 
three times a day, or meloxicam 15 mg orally, once a day. If  pain was present morphine 
was administered intravenously by patient controlled analgesia (PCA) pump (BRAUN, 
Melsungen, Germany). The settings of  the PCA pump were: basal rate 0.0mg /h, 
bolus dose 1.0mg, bolus interval 5 min, maximum 30 mg per 4 h. Pain was evaluated 
using visual analogue scores (VAS, ranging from 0 to 10: 0 = no pain, 10 = most severe 
pain). For each individual patient we assessed the maxi mum VAS score in the 24 h 
period and cumulative VAS scores, quantified as area under the curve (AUC) of  VAS 
scores during the 2 h period.
Statistical analysis
To detect a difference of  100 mL of  blood loss during surgery (SD ± 250 mL) with 
an a error (two sided) of  0.05 and a β error of  0.10, it was necessary to include 84 
patients per group.
Analysis of  interval scored data was performed using the Student’s t-test. Non-
parametric techniques (Kruskal–Wallis test) were used when necessary. Proportions 
were analysed with χ2 statistics and Fisher’s exact test. The α level for all analyses was 
set at P = 0.05. Data are reported as mean ± SD.
Results
In total 200 consecutive patients consented to par ticipate during the preoperative 
outpatient visit. How ever, at the time of  admission 32 patients had failed to stop 
use of  regular NSAIDs, mainly because of  pain. Of  the remaining 168 patients, 82 
were randomized to indomethacin and 86 were randomized to meloxi cam. Patient 
characteristics data of  these remaining patients are provided in Table 1. The two 
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groups were similar with regard to age, height, weight, gender, mean arterial pressure 
and heart rate.
 Table 1. Patient characteristics and intraoperative factors.
 Averaged data are shown as mean (SD). 
 n: number of  patients;  m: male;  f: female
Blood loss
Blood loss was significantly greater in patients pre treated with indomethacin than in 
those receiving meloxicam (Table 2). The volume of  blood loss dur ing operation was 
19% greater in the indomethacin group than in the meloxicam group (P < 0.01). 
Likewise, blood loss in the first 24 h after surgery was 15% greater in the indomethacin 
group than in the meloxicam group (P < 0.05). As a result, total blood loss (i.e. 
intraoperative blood loss plus blood loss during the first 24 h after surgery) was 17% 
greater in the indomethacin group than in the meloxicam group (P < 0.05).
 Table 2. Intra- and postoperative blood loss.
 Values are shown as mean (±SD). **P < 0.0 1; *P < 0.05 compared with 
 the indomethacin group. For details see text.
Group Meloxicam Indomethacin
n 86 82
Age (yr) 64 (10) 65 (10)
Height (cm) 168 (10) 171 (7)
Weight (kg) 75 (13) 77 (11)
Gender (m/f) 27/59 27/55
Duration of   67 (12) 69 (11)
surgery (min)
Mean arterial  105 (15) 107 (13)
pressure (mmHg)
Heart rate  74 (9) 75 (10)
(beatsmin21)
Group Meloxicam Indomethacin
Blood loss during 524** (304) 623 (243) 
surgery (mL)
Blood loss 24 h  358* (272) 410 (340)
after surgery (mL)
Total blood loss (mL) 882* (479) 1034 (486)
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Pain
VAS scores were <3 in the postoperative period in all patients in both groups (Fig. 1). 
Cumulative VAS scores were 6.1 for the indomethacin group and 5.3 for the meloxicam 
group (P > 0.05). Use of  sys temic morphine by PCA infusion pump was similar: 18 ± 
9 mg in the meloxicam group and 18 ± 7 mg in the indomethacin group.
 Figure 1. VAS pain scores 24 h after surgery.
Discussion
The major finding of  our study is that pretreatment with the COX 2-selective 
NSAID meloxicam results in less perioperative blood loss than use of  the non selective 
compound indomethacin. This data from clinical practice is consistent with in vitro 
studies that demonstrated the COX 2-selective action of  meloxi cam. However, several 
limitations of  the study should be kept in mind. We did not stratify patients by sur-
geon, as routine audit data from our hospital show very similar amounts of  blood 
loss among the surgi cal staff. However, this is a potential confounder. In addition, 
we did not determine if  the observed effects on blood loss had a significant impact 
on patient out come or management (e.g. hemoglobin concentra tion or transfusion 
requirements).
NSAIDs are used widely in orthopaedic surgery, but concerns remain about their 
tendency to increase intraoperative blood loss (1-3). This side-effect results from 
impairment of  platelet aggregation by block of  thromboxane formation, and could 
not be explained by an interaction between indomethacin and acenocoumarol (4, 5). A 
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breakthrough in the ability to sep arate the beneficial anti-inflammatory, analgesic and 
antipyretic action of  NSAIDs from these side-effects resulted from better insights in 
their mechanism of  action. NSAIDs inhibit COX, the major enzyme in the biosynthesis 
of  prostaglandins. In the early 1990s, it was recognized that the rate of  prostaglandin 
synthesis could increase dramatically when the formation of  a particular isoform of  
COX is induced by several cytokines or lipopolysaccharide. It is now known that COX 
exists in at least two isoforms, known as COX 1 and COX 2 (6, 7). COX 1 is found 
in the stomach, intestine, kidneys and platelets, and is essential for the synthesis of  
prostaglandins involved in important physiological processes, such as protection of  the 
gas trointestinal mucosa, maintenance of  renal function and circulatory homeostasis. 
This role of  COX 1 has been referred to as the ‘housekeeping’ function. In con trast, 
the inducible isoform COX 2 produces large amounts of  prostaglandins that mainly 
contribute to the pathophysiological process of  inflammation. Thus, the therapeutic 
effects of  NSAIDs are largely the result of  inhibition of  the enzyme COX 2, whereas 
adverse effects are primarily due to the inhibition of  COX 1.
It has been suggested that NSAIDs that selectively inhibit COX 2 have fewer side-
effects (6, 8). An exam ple is meloxicam, a NSAID derived from enolic acid which has 
a favourable COX 2/COX 1 ratio (9, 10). This ratio translates into fewer effects on 
platelet aggre gation in vitro. Indomethacin is a COX 2/COX 1 non-selective NSAID 
when tested in vitro, but shows a slight preference for COX 2 when tested ex vivo (11). 
Studies in vivo show contradictory results on the effects of  indomethacin on blood 
loss (12, 13). In this study we compared two different NSAIDs, which inhibit the two 
COX-isoforms to varying degrees.
More relevant to clinical practice is the question whether these data from in vitro 
studies and animal experiments translate in a decreased volume of  blood loss. The 
present study indicates that such is indeed the case: blood loss was approximately 20% 
less when meloxicam instead of  indomethacin was used. However, whether this is 
of  clinical significance and influences patient outcome remains to be deter mined. In 
addition, the potential beneficial effects of  these compounds on blood loss should be 
weighed against potential detrimental effects (such as a poten tially increased risk for 
cardiovascular events) before routine use can be recommended.
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Abstract
Introduction: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) prevent heterotopic 
ossification but gastrointestinal complaints are frequently.  Selective cyclooxygenase-2 
(COX-2) inhibiting NSAID produce less gastrointestinal side effects. 
Patients and methods: A prospective two-stage study design for phase 2 clinical 
trials with 42 patients was used to determine if  rofecoxib (a COX-2 inhibitor) 50 
mg oral for 7 days prevents heterotopic ossification. A cemented primary THA was 
inserted for osteoarthritis. After 6 months heterotopic bone formation was assessed on 
AP radiographs using the Brooker classification.  
Results: No heterotopic ossification was found in 81 % of  the patients, 19 % of  the 
patients had Brooker grade 1 ossification. 
Conclusion: Using a two-stage study design for phase 2 clinical trials, a 7-day 
treatment of  a COX-2 inhibitor (rofecoxib) prevents effectively the formation of  
heterotopic ossification after cemented primary total hip arthroplasty. 
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Introduction
Heterotopic ossification is a frequent complication after total hip replacement. Non-
Steroidal Anti-Inflammatory Drugs (NSAID) effectively prevent heterotopic ossification. 
In a systemic survey of  thirteen randomized trials using NSAID there was a fifty-seven 
percent reduction in the risk of  heterotopic ossification after total hip replacement 
(18). However, a treatment period of  at least five to seven days immediately after 
surgery is needed to prevent ossification (8, 10, 14, 15, and 26). Frequently reported 
serious side effects of  non-steroidal anti-inflammatory drugs are gastrointestinal 
complaints. In a prospective study with indomethacin, the most effective non-steroidal 
anti-inflammatory drug in preventing heterotopic ossification, eighteen percent of  the 
patients had to stop drug intake because of  these gastrointestinal side effects (7). 
Traditional non-steroidal anti-inflammatory drugs are inhibiting both cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2). In the last decade, selective cyclooxygenase-2 
(COX-2) inhibiting NSAIDs were introduced. These selective COX-2 inhibitors still 
work analgesic and anti-inflammatory, but produce less gastrointestinal side effects in 
comparison with non-selective NSAIDs (5, 21). This reduction makes these COX-2 
inhibitors attractive for the prevention of  heterotopic ossification. 
In literature, to our knowledge no data are available if  the reduction of  the heterotopic 
ossification after total hip arthroplasty in humans is a COX-1 or COX-2 effect or an 
effect of  a yet unknown pathway. 
The purpose of  this prospective study (a two-stage study design for clinical trials) 
was to determine if  seven days of  a COX-2 inhibitor (rofecoxib) effectively prevents 
heterotopic ossification after primary cemented total hip replacement.
	 Table	1.	Classification	of 	heterotopic	ossification	by	Brooker	(6).
Grade Bone formation
I Isolated bone islands
II Bone spurs from the pelvis or proximal femur, 
 space between opposing surfaces > 1 cm
III Bone spurs from the pelvis or proximal femur,   
 space between opposing surface< 1cm
IV Apparent bony ankylosis
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Materials and Methods
The local ethical committee approved this study. We used a two-stage study design 
for phase two clinical trials (22), in this design a small group is exposed to the 
experimental drug and only if  the effect in this small group is effective, the study 
group is expanded.  
For calculation of  the number of  cases needed in this two-stage study design, the data 
of  two historical patient-groups with total hip prostheses from our department were 
used (23). One group did not receive any prophylaxis and the second group received 
7 days of  indomethacin (Table 2). In the group without prophylaxis 29 % developed 
grade 3 or 4 HO, so 71 % did not; in the indomethacin group only 2% developed 
grade 3 or 4 HO and 98% did not. Given these data, a treatment of  seven days with 
a COX-2 inhibitor (rofecoxib) was considered effective only if  at least 80 % of  the 
cases had a Brooker classification 0, 1 or 2; because without treatment 71% of  patients 
do not develop grade 3 or 4 HO. On the other hand a drug with which less than 5% 
develop grade 3 or 4 HO needs to be detected with a high probability given the results 
of  the historical treatment group.
So in the two-stage Simon design (22), with an actual effectiveness of  less than 80% 
the medication (rofecoxib) is not to be recommended (accept the corresponding 
hypothesis with probability (1 -α = 0,95). An actual effectiveness of  at least 95 % 
needs to be detected with a high probability (≥ 90%). When entering these data in the 
table in the article by Simon (22) or using his software the number of  patients needed 
can be calculated. For the first stage of  this study design, 19 cases were necessary. Six 
months after surgery radiographs are scored using the Brooker classification (table 1). 
At least 17 patients with a Brooker classification 0, 1 or 2 have to be found in order 
to proceed to the second stage. The second stage has to be completed with another 
twenty-three patients. Treatment is declared promising if  at least 38 patients with a 
Brooker classification 0, 1 or 2 are found in 42 patients. 
Inclusion criteria for this study were patients with primary or secondary hip osteoarthritis 
who were listed for a cemented primary total hip arthroplasty. Exclusion criteria were: 
rheumatoid arthritis, ankylosing spondylitis, femoral neck fractures, previous allergic 
reaction on non-steroidal anti-inflammatory drugs, gastrointestinal complaints at 
admission, a history of  gastrointestinal ulcers or perforations, inflammatory bowel-
disease, hepatic dysfunction, renal dysfunction with a clearance below 30 ml/min and 
cardiac insufficiency.
All included patients signed the informed consent form. The administration of  NSAID 
was ceased ten days before surgery, if  necessary acetimophen (Paracetamol) and 
tramadol were allowed to relieve pain. The evening before surgery patients received 
the first dose of  rofecoxib, 50 mg orally, followed by 6 days of  50 mg rofecoxib orally 
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in the evening. Patients were not allowed to use any other NSAID, except the study 
medication, during the first two months after surgery. If  pain has to be relieved patients 
were allowed to take acetimophen, tramadol or narcotics. Gastrointestinal complaints 
were recorded daily up to 7 days after operation. Gastrointestinal complaints were 
scored as nausea, dyspepsia, pyrosis, vomiting and other gastrointestinal complaints. 
If  patients used medication because of  gastrointestinal complaints prior to surgery 
they were allowed to continue this medication during the trial period; the use of  
this medication was recorded. Patients received pantoprazol 40 mg a day if  severe 
gastrointestinal complaints occurred during the first 7 days after operation. 
In all patients, a posterolateral approach without trochanteric osteotomy was used 
and a cemented total hip prosthesis (Exeter total hip prosthesis, Stryker Howmedica, 
Newbury, UK) was inserted. The patients received antibiotic prophylaxis at the start 
of  the operation (Cefazolin, 2 gram intravenously). Antithrombotic prophylaxis was 
established by low molecular-heparin (nadroparin 10,000 IE a day, subcutaneous) 
during the first six weeks after the operation, starting at the evening before operation. 
Suction wound drainage was used for two days. Two days after surgery full weight 
bearing was allowed, with the use of  two crutches.
Clinical examinations were performed the day before surgery, at six weeks and 
six months after the operation. A Harris hip score was obtained. Radiographic 
examinations were routinely performed immediately after operation, at six weeks 
and six months after surgery. Conventional anteroposterior pelvic radiographs were 
assessed; the classification of  heterotopic ossification by Brooker (6) was used. The 
radiographs were evaluated by an experienced orthopedic radiologist (J.A.M.L.) and 
an orthopedic surgeon (R.C.T.K.) on a consensus base. To prevent bias all radiographs 
of  the patients of  the study group were mixed with radiographs of  a group of  matched 
patients, who were operated in the year before this study, using the same operation 
technique and implant. All radiographs were coded and the name and birth-date of  
the patients were blinded.
Results
Nineteen patients were included (10 women, 9 men) for the first stage of  the study. 
The indication for the hip replacement was primary osteoarthritis in 11 and secondary 
arthritis in 8 hips. During the second phase of  the study twenty-three patients were 
included (12 women, 11 men); no patients were lost.
The diagnosis was osteoarthritis in all patients of  this study (primary osteoarthritis 
in 30 and secondary osteoarthritis in 12 hips; congenital hip dysplasia 3, avascular 
necrosis 4, slipped capital femoral epiphyseolysis 2, Perthes disease 2, and post septic 
1). The average age of  the whole group at surgery was 62 (28-83) years.
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One initially included patient in stage 1 of  the study refused to continue rofecoxib 
after five days, because of  nausea and pyrosis starting at the third postoperative day. 
Although this patient received pantoprazol he reported persistent gastrointestinal 
complaints and refused to continue rofecoxib. This patient was excluded from the 
study. However for the used study design it is essential that all patients complete the 
protocol so the patient was replaced. 
All nineteen patients who were included for the first stage of  this two-stage design study 
completed the seven days protocol of  rofecoxib and were available for follow-up. After 
six months the radiographs were analyzed for heterotopic ossification: 15 patients had 
a Brooker grade 0 and 4 patients a Brooker grade 1. These data were entered in the 
two-stage study design. At least 17 patients with a Brooker classification 0, 1, or 2 had 
to be found in order to proceed to the second stage. In the first stage-group of  this 
study all patients had a Brooker classification 0, 1 or 2. The criteria required for the 
first stage were fulfilled and the second phase was started. 
All twenty-three patients, included for the second stage, completed the seven-day 
protocol. In the second stage no patients were lost to follow-up. After six months 
the radiographs of  the patients of  the second stage were analyzed for heterotopic 
ossification: 19 patients had a Brooker grade 0 and 4 patients a Brooker grade 1. 
At the end of  the study the results of  the patients of  the first and second stage were 
combined. No heterotopic ossification was found in 34 of  the 42 patients (81 %). 
Brooker grade 1 ossification was found in 8 patients (19%) and 0 patients grade 2. No 
widespread ossification (Brooker grade 3 and 4) was seen in this study.  These data 
were entered in the two-stage study design. The probability of  an inhibitory effect of  
rofecoxib on heterotopic bone formation was calculated to be 100 % (95 %-confidence 
interval: 91,6 % - 100 %). This study showed that, using a two-stage study design 
for phase 2 clinical trials, a 7-day treatment of  a COX-2 inhibitor (rofecoxib) is a 
promising method to prevent the formation of  heterotopic ossification after cemented 
primary total hip arthroplasty. 
At clinical examination before and six months after the operation we obtained the 
Harris Hip Score. The mean Harris Hip Score significantly improved (p < 0.05) from 
pre-operatively 52 (range 19-87) to 87 (range 49-100), six months after surgery. The 
incidence of  gastrointestinal complaints was 26 %. In 4 patients pantoprazol was given 
because of  gastrointestinal complaints and one patient received, by mistake, cimetidine 
instead of  pantoprazol. No patients had severe gastrointestinal side effects, such as 
bleeding or perforations. Four patients used medication (three patients omeprazol and 
one patient ranitidine) because of  gastrointestinal complaints prior to surgery and 
were allowed to continue this medication during the trial period; two of  these patients 
reported nausea the first two days after surgery. 
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	 Table	2.	Heterotopic	ossification	after	primary	cemented	total	hip
	 Arthroplasty	in	the	two	historical	patient	groups	(indomethacin	and	no	prophylaxis)	used	
	 for	calculation	of 	the	two	phase	study	design	and	the	incidence	in	the	group	
	 which	received	rofecoxib.
Complications
Three patients had a total of  five dislocations of  the hip, all occurred within 6 weeks 
after surgery. All were treated conservatively. Four patients had a superficial wound 
infection with a good response to antibiotics, one patient a deep venous thrombosis, one 
patient pulmonary emboli and two patients had visual problems after the operation. 
None of  the patients underwent re-surgery.
Discussion
Rofecoxib, a COX-2-specific inhibitor, in a dose of  50 mg for seven days seems to be a 
promising prophylaxis of  heterotopic ossification after primary total hip arthroplasty in 
this 2-phase study. Almost all nonselective NSAIDs decrease the incidence of  HO after 
primary THA (18). However only few reports are published about the prophylactic 
effect of  this new class of  COX-2 specific drugs.  Meloxicam was one of  the first drugs 
which claimed to be COX-2 selective; from this drug three reports were published. 
Barthel (4) found an inferior effect for meloxicam as compared to indomethacin, two 
other studies showed no difference between indomethacin and meloxicam (17, 24).
From the high selective COX-2 inhibitors, data are lacking about the prophylactic 
effect on HO. One study by Romano (20) described the prophylactic effect of  
celecoxib, which was comparable to the effect of  indomethacin. Furthermore they 
found that fewer patients in the celecoxib group had to discontinue their medication 
due to side-effects.
Brooker Indomethacin  No prophylaxis Rofecoxib 
grade 7 days (170 patients) 7 days
 (99 patients)  (42 patients)
0 72 (73%) 40 (24%) 34 (81%)
1 24 (24%) 33 (19%) 8 (19%)
2 1 (1%) 48 (28%) -
3 1 (1%) 29 (17%) -
4 1 (1%) 20 (12%) -
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To our knowledge the only paper describing the effect of  rofecoxib on HO, is the study 
by Banovac et al. (3), who describe the prophylactic effect on HO after spinal cord 
injury as compared to placebo.
Although both rofecoxib and valdecoxib are withdrawn from the market due to their 
elevated cardiovascular risk with longterm use, this increased risk was not found after 
short term use. Maybe the prevention of  HO is COX-2 mediated and this class of  
medicines may be important in prophylaxis of  HO after THA.
The benefit of  this class of  drugs is a decrease of  gastrointestinal complaints and 
complications (9, 16). Because these drugs do not affect platelet function, the 
perioperative blood loss can be decreased (25).
Although several animal studies show a decreased fracture healing and implant 
ingrowth when NSAIDs, and especially when specific COX-2 inhibitors are used (11, 
12, 19), little is known about this effect in humans. Despite the understanding of  the 
potential mechanism through which NSAIDs inhibit bone healing in a laboratory 
setting, few studies are available that show whether these inhibitory effects are 
also evident clinically (13). Given the two additional risk factors, i.e. the increased 
cardiovascular risk after long-term use and the potential decrease of  bone ingrowth in 
uncemented prosthesis (1, 2) this class of  drugs has also to be investigated on these two 
aspects before widespread use is recommended.
The fact that the inhibition of  COX-2 is correlated with the prevention of  heterotopic 
ossification after total hip arthroplasty could be a key to further research to discover 
how heterotopic ossification develop and how this formation process can be prevented. 
Further studies are needed, to show the benefits and the hazards of  this relatively new 
class of  drugs.
We used this two phase study design as we did before (23) to limit the number of  
patients exposed to a potentially inferior treatment. In this design the first number of  
patients is limited and the group is only expanded when in the first group of  patients 
only an amount of  patients develop HO which is comparable with a group which 
received indomethacin. For this study design it is paramount to fulfill the criteria about 
the number of  included patients, which was the reason to replace the excluded patient 
from the trial. 
Although rofecoxib was withdrawn from the market by Merck in September 2004, we 
think the current study is still interesting because little is known about the effect of  the 
selective COX-2 inhibitors on HO.
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Conclusion
The prophylactic effect of  rofecoxib on HO after THA is promising. With the numbers 
available in this two-phase study design the effect is comparable with the effect of  
indomethacin.
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Similar effect of  rofecoxib and indomethacin on HO after THA
Abstract
Background: Although indomethacin is effective in preventing heterotopic 
ossification (HO) after primary total hip arthroplasty, side effects are frequently 
observed. In the last decade a new class of  drugs, the COX-2 selective non-steroidal 
anti-inflammatory drugs, has been developed. To investigate the effect of  these COX-2 
selective NSAID on heterotopic ossification (HO) after primary total hip arthroplasty 
(THA) we conducted a randomized controlled trial using either indomethacin or 
rofecoxib for 7 days.
Methods: 186 patients received either indomethacin three times daily, or rofecoxib 
twice daily and one placebo for 7 days. HO was graded on the 1-year postoperative 
radiographs according to the Brooker classification. 
Results: 12 of  186 included patients discontinued their medication before the end of  
the trial due to side effects. The remaining 174 patients were included for analysis. In 
the indomethacin-group (n=89), 77 patients (87%)  showed no HO, 9 showed grade 1 
and 3 showed grade 2 according to the Brooker classification. In the rofecoxib-group 
(n=85) 73 patients (86%) showed no ossification, 9 showed grade 1 and 3 showed 
grade 2.
Interpretation: The prophylactic effect of  rofecoxib for 7 days in preventing 
heterotopic ossification after primary total hip arthroplasty is comparable to the effect 
of  indomethacin given for 7 days. These results indicate that the formation of  HO 
follows a COX-2 pathway. 
75
6
C
hapter
Introduction
Although indomethacin is effective in preventing heterotopic ossification (HO) after 
primary total hip arthroplasty (22, 26), side effects are frequently observed. The 
minimum treatment period for NSAIDs seems to be 7 days (26). Indomethacin used for 
3 (30) or 4 (16) days showed inferior results. Traditional non-steroidal anti-inflammatory 
drugs are inhibiting both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). 
In recent years, selective COX-2 inhibitors have been developed; these provide 
comparable pain reduction with fewer side effects (7, 18, and 29) and a reduced 
perioperative blood loss (32). Due to this reduction in side effects, these COX-2 
inhibitors are attractive to use for the prevention of  heterotopic ossification. 
To our knowledge no data are available in literature concerning whether the reduction 
of  the heterotopic ossification after total hip arthroplasty in humans is a COX-1 or 
COX-2 effect or an effect of  a yet unknown pathway. To investigate the incidence of  
heterotopic ossification (HO) after primary total hip arthroplasty (THA) we conducted 
a double-blind randomized controlled trial for prophylaxis using either indomethacin 
or rofecoxib for 7 days.
Patients and methods
After approval by the local ethics committee, the study was initiated in the Rijinstate 
Hospital, Arnhem, the Netherlands, which is a teaching hospital. The inclusion and 
exclusion criteria were as follows. Inclusion criteria:  primary total hip arthroplasty, 
spinal or epidural anesthesia, able to sign informed consent, age between 18 and 85 
years. Exclusion Criteria: previous surgery on the same hip joint, included in another 
study, any history of  bleeding disorders, any history of  gastric ulcer, or rheumatoid 
arthritis. All patients who were included signed a written informed consent. A power 
analysis was performed to calculate the number of  patients needed for this study. 
From this calculation, we intended to include 200 patients. However the inclusion of  
patients for this study was terminated on the day Merck withdrew rofecoxib from the 
market, i.e. September 30, 2004 (11, 15). At that time 186 patients were included (58 
males and 116 females). All non-steroidal-anti-inflammatory drugs were stopped 10 
days before surgery. Patients started their medication on the morning of  surgery and 
continued it until the sixth postoperative day; thus the trial period was 7 days. Each 
patient who was included received a package with 21 capsules, 7 labeled “morning”, 
7 “afternoon” and 7 “evening”. The medication was repacked in numbered packages 
and the pharmacologist executed the randomization procedure. The packages 
were used under code by both patients and physicians. In the rofecoxib-group, the 
patients received 3 capsules a day; the morning and evening tablet consisted of  25 
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mg rofecoxib, the afternoon tablet was a placebo. In the indomethacin group, patients 
received indomethacin (50 mg) 3 times a day. No other NSAIDs were allowed for two 
months postoperatively. When necessary, patients were allowed to take acetominophen 
(Paracetamol).
All hips were implanted using the posterolateral approach and all patients received 2 
g Cefazolin i.v. before surgery. A suction drain was used, which was removed on the 
first or second day postoperatively. All patients started weight bearing mobilization 
at the first postoperative day. Thrombo-embolic prophylaxis was given by a daily 
subcutaneous injection of  0,3 ml nadroparin (Fraxiparine) (2850 IE) for 6 weeks.
All patients were reviewed 1 year postoperative by one investigator (H.v.d.H.), and the 
pelvic radiographs were scored for HO according to Brooker (8). The investigator was 
blinded for the prophylactic treatment given to the patient.  
 We used SPSS-statistics (Version 11.5, SPSS, Chicago, Illinois, USA) for statistical 
analysis. The incidence of  HO was estimated in both groups. Confidence intervals 
for these estimates were computed using the normal approximation to the binomial 
distribution, as was the confidence interval for their difference.
Results
12 patients (7%) of  the 186 patients who were included discontinued their medication 
before the end of  the trial due to side effects, mainly nausea and vomiting (6 in the 
indomethacin group and 6 in the rofecoxib group), and they were excluded from 
further analysis. Of  the remaining 174 patients 86% (95% CI 78-93%) showed no 
signs of  HO in the rofecoxib-group compared with 87% (95% CI 79-94%) in the 
indomethacin group (Table 2). This difference (1%, 95% confidence interval –10 to 
11%) was not significant (p = 0.9). 
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 Table 1: The distribution of  HO between the two different treatment groups, 
 no difference was found.
Discussion
We found no difference between the selective COX-2 inhibitor rofecoxib and 
indomethacin in the prevention of  heterotopic ossification after primary THA. 
Considering the effectiveness of  NSAIDs (22, 26) and the fact that in our hospitals all 
patients receive standard NSAID prophylaxis for HO, from an ethical point of  view 
we elected not use a placebo-controlled study design. 
Although indomethacin is a powerful drug to prevent heterotopic ossification, the 
high incidence of  side effects (26) poses a clinical problem. Knelles (22) showed 
22 % side effects which resulted in study withdrawal of  2 %. Cella et al (10) found 
contraindications to indomethacin in one fifth of  patients and one third of  their 
patients were withdrawn from the study.
Given the side effects of  indomethacin, several other NSAIDs have been investigated 
for their prophylactic effect on HO. In recent years, more COX-2 selective inhibitors 
have been developed, with less side-effects (7, 18, 19, 24) and the same pain reducing 
effects (13, 14, 18, 21, 28). The effect on HO of  this newer class of  NSAIDs is described 
circumstantially: the effect of  meloxicam is contrasting, some studies show the same 
effect (25, 31), an other showed inferior results (5). The effect of  celecoxib is described 
by Romano (27) and is comparable with the effect of  indomethacin. The latter authors 
found, however, fewer patients in the celecoxib group who had to discontinue their 
medication due to the side effects as compared to the indomethacin group. In our 
group the number of  patients who stopped their medication before the seventh day is 
similar to these results (7%). In our study it is striking, that the number of  patients that 
stopped their medication due to the side effects, is exactly the same in both groups.   
To our knowledge there have been no publications reporting the effect of  rofecoxib 
Heterotopic  Indomethacin Rofecoxib
Ossification (n=89) (n=85)
Brooker Grading
Grade 0 77 (87%) 73 (86%)
Grade 1 9 (10%) 9 (11%)
Grade 2 3 (3%) 3 (3%)
Grade 3 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%)
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on HO after primary total hip replacement. The only paper addressing the possible 
effect of  rofecoxib on HO is the study by Banovac et al. (4). However, these authors 
described the prophylactic effect on HO after spinal cord injury. Although rofecoxib is 
withdrawn from the market, we think the current study is still interesting because little 
is known about the effect of  the selective COX-2 inhibitors on the incidence of  HO. It 
is likely that the prophylactic effect of  rofecoxib is a class-effect for all COX-2 selective 
inhibitors and this study adds information concerning the effect of  this specific group. 
Furthermore, rofecoxib may perhaps be re-introduced onto the marked for short term 
use. Another important advantage of  this new class of  drugs may be the reduction of  
perioperative blood loss. Kristensen et al (23) found increased perioperative blood loss 
after the use of  indomethacin, due to the reduction in platelet aggregation. Weber et 
al. (32) found a decrease in per and postoperative blood loss of  15% in the meloxicam 
group compared to the indomethacin group. However, serious concerns have been 
raised about the possible deleterious effect of  NSAIDs -and especially of  the COX-2 
selective ones- on bone healing and bone ingrowth in implants (1, 3, 9, and 12). Given 
the two additional risk factors, i.e. the increased cardiovascular risk after long-term use 
and the potential decrease of  bone ingrowth in uncemented prosthesis (2, 3) this class 
of  drugs must also be fully investigated regarding these two issues before widespread 
can be recommended.
In conclusion, the prophylactic effect of  giving rofecoxib for seven days for prevention 
of  heterotopic ossification after primary total hip arthroplasty is comparable to the 
effect of  indomethacin given for seven days.
Note added in proofs
A similar study, which we were unaware of, is also published in this issue of  Acta 
Orthopaedica (20)
The other study shows the same results as ours, but the incidence of  HO was much 
higher in both treatment arms. This can be explained by the surgical (anterolateral) 
approach used in their study. A posterolateral approach was used in our study. It is 
known from the literature that the incidence of  HO using an anterolateral approach 
is higher (6, 17). 
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Abstract
Background and purpose: There is a rising awareness that non-steroidal anti-
inflammatory drugs (NSAIDs) and especially the cyclooxygenase-2 (COX-2) selective 
ones may retard bone healing. We have used NSAIDs (indomethacin for at least 7 days) 
to prevent heterotopic ossification after acetabular reconstructions using impacted 
bone grafts. The long-term clinical results have been satisfying, making it hard to 
believe in an important negative effect of  NSAIDs on graft incorporation. Therefore, 
we studied the effect of  two different NSAIDs on bone and tissue ingrowth in a bone 
chamber model in goats using autograft, rinsed allograft, and rinsed and subsequently 
irradiated allograft.
Methods: 9 goats received no NSAIDs, 9 received ketoprofen, and 9 received 
meloxicam, all for 6 weeks. In each goat 6 bone chambers were implanted, 2 filled with 
autograft, 2 with rinsed allograft and 2 with irradiated rinsed allograft. The amount of  
bone and total tissue ingrowth was compared between the groups. 
Results: No difference was found in bone ingrowth between the different groups, 
furthermore no difference was found with respect to the type of  graft used. Also the 
total amount of  fibrous tissue ingrowth did not differ between the treatment groups.
Interpretation: No difference in bone ingrowth in titanium bone chambers in 
the goat could be detected with both ketoprofen and meloxicam compared with no 
medication. This confirms our hypothesis that the effect of  NSAID on the incorporation 
and ingrowth of  bone graft is limited.
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Introduction
There is both experimental and clinical evidence of  inhibition of  new bone formation 
by NSAIDs (both selective and non-selective) (8, 10, 19). NSAIDs inhibit bone ingrowth 
in porous implants (8, 22), delay fracture healing (19), inhibit spinal fusion in rats (5), 
and inhibit experimental bone induction (16). Clinically, NSAIDs have been found to 
retard healing of  diaphyseal fractures (3) and spinal fusions (7) 
NSAIDs are also very effective in preventing heterotopic ossification (HO) after total 
hip arthroplasty (14), strongly suggesting that these drugs also have effects on human 
bone formation on ectopic places. Theoretically, these NSAIDs inhibit bone restoration 
which may result in a less stable or even unstable implant (15). 
The effect of  NSAIDs could be even more devastating if  they are combined with bone 
grafts to reconstruct bone defects.  An inhibiting effect of  NSAIDs on bone repair 
could also jeopardize the ingrowth into these grafts. 
We have used NSAIDs (indomethacin for at least 7 days) to prevent heterotopic 
ossification with acetabular reconstructions in both primary and revision hip surgery. 
The long-term clinical results are satisfying, making it hard to believe that NSAIDs 
have an important negative effect on graft incorporation (18, 26). Also in a study on 
the outcome of  femoral revision with bone impaction grafting at minimal 10 years the 
administration of  indomethacin did not seem to influence the long-term results (17).
We studied the effect of  2 different NSAIDs on bone and tissue ingrowth in a bone 
chamber model in goats using autograft, rinsed allograft, and rinsed and subsequently 
irradiated allograft. We hypothesized that the effect of  NSAID on the incorporation 
of  bone grafts is limited.
Materials and methods
Experimental design
30 mature Dutch milk goats (Capra Hircus Sana) (48–61 kg) were obtained from the 
Central Animal Laboratory, Nijmegen, The Netherlands. 
Allograft bone was obtained from the sternum of  3 donor goats; the other 27 
goats were divided into 3 groups. The first group did not receive any NSAID, the 
second group received ketoprofen (non-selective NSAID) (2.2 mg/kg) once daily 
subcutaneously, the third group received meloxicam (COX-2 preferential) (0.5 mg/
kg) once daily subcutaneously. The treatment period was 6 weeks for all goats. The 
treatment regimen for both ketoprofen and meloxicam in goats was based on the 
literature (1, 13). All procedures were approved by the Animal Ethics Committee of  
the Radboud University Nijmegen, The Netherlands.
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Preparation of  grafts
3 donor goats were used to obtain allograft from the sternum. These goats were killed 
by an overdose of  pentobarbital and the sternum was excised under aseptic conditions. 
All spongious bone from the sternum was retrieved and rinsed with sterile saline 
using a high-pressure pulsatile lavage system (SurgiLav® Plus, Stryker Nederland BV, 
Waardenburg, The Netherlands). All bone from the these 3 goats was pooled and 
divided in 2 parts. The first part was used without further processing, the second part 
was irradiated with 25 kGy using a 60Co gamma-ray source (Isotron B.V., Ede, The 
Netherlands) at a temperature of  –78.5 ºC (dry ice). Both allograft and irradiated 
allograft were stored at – 80 ºC and thawed just before implantation.
Implants
We used the bone conduction chamber (BCC), which is a model for membranous 
ossification (2, 25). The BCC consists of  a titanium screw with a cylindrical interior 
space. It is made up of  two threaded half-cylinders held together by a hexagonal 
closed screw cap. The interior of  the chamber has a diameter of  2 mm, and a length 
of  7.5 mm. There are two ingrowth openings for bone ingrowth located at the bone 
end of  the chamber. Originally developed as a rat model, we adjusted the BCC for 
use in goats. The threaded end of  the implant is screwed into the bone, allowing 
direct contact of  the ingrowth openings with the endosteal transition from marrow 
into bone. To accomplish this in goats, a 1-mm thick plate was inserted into the cap to 
lower the ingrowth openings through the cortex (9, 24)
Surgical procedure
Anesthesia was accomplished by intravenous administration of  pentobarbital (CEVA 
Sante´ Animale, Maasluis, NL) (0.5 mL/kg) and maintained after intubation with 
nitrous oxide, oxygen and isoflurane (1.5–2%). In all 27 goats autograft was obtained 
from the right femoral condyle under aseptic conditions. A longitudinal incision was 
made along the lateral epicondyle and just ventral of  the iliotibial tract a hole was 
made by a hollow drill of  7.3 mm and a plug of  corticospongious bone was retrieved, 
the spongious part of  this plug was used as autograft. 
The goats received 3 chambers at each side in the cortical bone of  the proximal medial 
tibia. 1 chamber at each side was filled with autologous graft, 1 with rinsed allograft, 
and the third with irradiated rinsed allograft. A longitudinal incision was made in the 
skin and fascia over the medial side of  the proximal tibia. After raising the periosteum, 
a hole was drilled through the medial cortex at approximately 4 cm from the joint cleft 
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using a 3.1 mm drill. The hole was tapped and bone debris from drilling was removed. 
The bone chamber was screwed in manually. The second bone chamber was placed 
at a distance of  10 mm from the first one, the third was placed again 10 mm lower. 
This was repeated for the other side. The position of  the different grafts was changed 
to different positions in different cases, to avoid linking of  the different variables (for 
example all autografts in the proximal position). The subcutaneous layer and the skin 
were sutured. All animals were allowed unrestricted movement in their cages and had 
free access to water and food after the operation. After the implantation procedure the 
animals received subcutaneous ampicillin (15 mg/kg/48 h) 3 times. 
Evaluation
After 6 weeks all goats were killed with an overdose 
of  pentobarbital. Tibiae were removed, and the 
bone chambers with surrounding cortex were fixed 
in 4% buffered formalin. After 1 day the content was 
removed from the chambers and fixed additionally. 
The specimens were dehydrated using ethanol and 
embedded in polymethylmetacrylate (PMMA). The 
specimens were cut with a microtome parallel to 
the longitudinal axis of  the chamber. Sections were 
taken at 0, 300 and 600 μm from the center of  the 
specimens, each section 5 μm thick. The sections were 
stained with hematoxylin and eosin and with Goldner-
Masson trichrome for routine histology. All sections 
within each experiment were investigated in random 
order. 
 Figure 1
 Example of  typical bone ingrowth in bone  
 chamber, Hematoxylin and eosin, original   
	 magnification	12.5x.This	goat	received		 	
	 meloxicam	and	a	rinsed	allograft	was	used.			
	 Nonvascularized	remnants	of 	the	graft	(G)	
	 at	the	top	of 	the	chamber.	A	fibrous	ingrowth		
	 zone	(F)	between	the	graft	and	the	newly	formed		
	 bone,	and	a	zone	of 	newly	formed	bone		(B)	
	 at	the	bottom	of 	the	chamber.
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Histomorphometric analysis was performed by using interactive computer controlled 
image analysis (analySIS, Soft Imaging System GmbH, Münster, Germany). The 
bone ingrowth distance in each slide was calculated by dividing the new bone area by 
the width of  the specimen. In all specimens marrow cavities surrounded by bone were 
included in the bone area. The mean of  the 3 sections at 0, 300 and 600 μm from the 
center yielded a value for the specimen. The total tissue ingrowth distance, which is 
the distance from the ingrowth end to the fibrous ingrowth frontier, was measured in 
the same way as bone ingrowth (20).
Statistics
We applied two outcome measures, fibrous tissue ingrowth and bone ingrowth, each 
possibly related to medication (none, ketoprofen or meloxicam), graft type (autograft, 
rinsed allograft or irradiated rinsed allograft), side (left or right leg) and position of  the 
bone chamber (proximal, distal or middle).
For each of  the two outcome measures a general linear model for repeated 
measurements (within a goat) was postulated. We assumed that all 6 variables within a 
goat were correlated. These models were subsequently analysed with PROC MIXED 
of  the SAS system (SAS international, Heidelberg, Germany). P-values less than 0.05 
were considered to be significant. The smallest relevant difference in ingrowth was set 
at 0.8 mm. The study was designed to have 80% power in detecting this difference of  
0.8 mm between the means of  all groups, and a standard deviation of  this mean of  
0.5 mm.
Results
Clinical evaluation
1 goat (no NSAIDs) died after 2 weeks, due to an unknown pregnancy and complicated 
delivery. All other goats performed well and loaded their legs fully at the first day after 
surgery. With the preparation of  the grafts, 1 bone chamber was lost (autograft from 
the ketoprofen group), resulting in a total of  155 samples.
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Histologic analysis
21 of  the bone chambers showed no ingrowth or only fatty tissue and no fibrous tissue 
or bone (5 in the group without medication, 2 autografts, and 3 irradiated autografts; 
7 in the ketoprofen group, 5 autografts, and 2 irradiated allografts; 5 in the meloxicam 
group, 1 autograft, 2 allografts, and 2 irradiated allografts). The remaining 134 
specimens showed a typical ingrowth pattern. Nonvascularized remnants of  the graft 
were present in the top of  the chamber. A fibrous ingrowth zone was present between 
the graft and the newly formed bone, and a zone of  newly formed bone was located at 
the bottom of  the chamber (Figure 1). In all treatment groups the newly formed bone 
consisted of  immature woven bone in a fibrovascular stroma (Figures 2 and 3). 
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	 Figure	2
	 Typical	histological	section	from	a	sample	of 	a	graft	from	a	goat	which	received		 	
	 ketoprofen,	stained	with	hematoxylin	and	eosin,	original	magnification	50x.	
	 Newly	formed	woven	bone	(NB)	in	a	fibrovascular	stroma	(FS)	can	be	seen,	with	vital		
	 osteoblasts	(*)	and	osteoclasts	(C)	surrounding	the	newly	formed	bone.
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 Figure 3
	 Typical	histological	section	from	a	sample	of 	a	graft	from	a	goat	which	received		 	
	 meloxicam,	stained	with	hematoxylin	and	eosin,	original	magnification	50x.	New	woven	
	 bone	(NB)	in	a	fibrovascular	stroma	(FS),	with	osteoblasts	(*)	and	osteoclasts	(C)		 	
	 comparable	to	the	bone	formation	in	goats	receiving	ketoprofen.
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Histomorphometry
No difference in bone (p=0.5) or fibrous tissue ingrowth (p=0.6) was found between the 
different medication groups (Table 1), including the group not receiving any NSAIDs 
(tables 1 and 2). 
No difference in bone ingrowth was found with respect to graft type (p=0.4), position 
of  the bone chamber (p=0.6) or operated leg (p=0.6) (Table 3). 
In contrast, we found a higher total tissue ingrowth in the irradiated rinsed bone graft 
as compared to the other 2 graft types (p=0.01), no left to right difference (p=0.05) 
and a higher total amount of  tissue in the proximal bone chamber as compared to 
the middle and distal ones (p=0.001). No difference in total tissue ingrowth was found 
when comparing the different medication groups (p=0.6). 
	 Table	1:	Bone-	and	fibrous	ingrowth	in	mm	(SD)
	 Table	2:	Bone	ingrowth	in	the	different	medication	groups
 No medication Ketoprofen Meloxicam
 bone tissue bone tissue bone tissue
autograft 0.5 (0.6) 3.9 (1.1) 1.0 (1.1) 4.5 (1.6) 0.9 (1.0) 4.1 (1.2)
allograft 0.8 (0.8) 4.1 (1.2) 1.0 (1.8) 4.2 (1.3) 1.0 (0.8) 4.1 (1.1)
irradiated  1.0 (1.0) 4.1 (1.5) 0.8 (0.7) 4.5 (1.4) 1.1 (0.9) 4.5 (1.3)
allograft
Medication	 Difference	observed	in	mm	 Confidence	interval	 P-value
No medication                  -0.14 -0.66- 0.38 0.6
versus  (no medication lower
ketoprofen  than ketoprofen)
No medication                 -0.3   -0.82- 0.22 0.2
versus  (no medication lower
meloxicam than meloxicam)
Ketoprofen                  -0.16  -0,69- 0.34 0.5
versus  (ketoprofen lower than
meloxicam meloxicam)
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	 Table	3:	Tests	of 	fixed	effects,	relation	of 	bone	ingrowth	with	graft	type,	medication,	
 side and position of  the bone chamber
Discussion
Although there is sufficient evidence that NSAIDs give a reduction in fracture healing 
and bone ingrowth in smaller animals, the effects of  these drugs on bone graft 
incorporation in humans and larger animals seems to be limited. The good results of  
THA despite the use of  NSAIDs as prophylaxis for HO, makes it hard to believe that 
the effect of  NSAIDs on bone ingrowth is as large as it is in smaller animals.
We found no difference in bone ingrowth in titanium bone chambers in the goat either 
with ketoprofen or meloxicam compared with no medication. Furthermore there was 
comparable bone ingrowth whether an autograft, rinsed allograft or irradiated rinsed 
allograft was used. The findings of  the same ingrowth in rinsed allograft and autograft 
are similar to the findings of  van der Donk et al. (23) who found that with rinsing, total 
tissue ingrowth increased in the allograft group to approach that of  autografts. The 
effect of  lipid extraction from allografts, which enhances bone ingrowth, has been 
described before by Thorén et al. (21). The similar ingrowth between rinsed allografts 
and irradiated rinsed allografts are in line with the findings of  Hannink et al. (9)
The bone chamber model we used was developed by Aspenberg and Wang (2). In this 
animal model a single factor can be changed, to evaluate its effect on bone ingrowth. 
Although the effect of  physical load can not be studied in this model, it is valid for 
detecting the effects of  bone substitutes and signalling molecules involved in bone 
metabolism that arise in unloaded conditions (20). Most bone chamber studies have 
been performed in smaller animals, especially rats and mice (6, 8, 19). It is possible 
 Degrees of  freedom F-value P-value
graft type 2 0.92 0.4
medication 2 0.73 0.5
side 1 0.28 0.6
position 2 0.60 0.6
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that the pharmacological and pathophysiological regulation of  COX or the properties 
of  the isoenzymes in different animal species differs, thus when anti-inflammatory 
effects of  NSAIDs are determined in animal experiments based on COX inhibition, 
species differences must be taken in to account (4). The ingrowth itself  in this animal 
model shows comparable ingrowth in rats and goats (24). We used goats, because we 
think the bone metabolism in goats is similar with the human bone metabolism, as 
compared to the metabolism in mice or rats. Furthermore the pharmacokinetics and 
pharmacodynamics of  the drugs we used are known (1,13) 
Although we wanted to use a COX-2 selective NSAID, we used the COX-2 preferential 
drug meloxicam because this is the only one from which the pharmacokinetics and 
pharmacodynamics have been studied in the goat. For the same reason we choose 
ketoprofen as a non-selective NSAID (1,13). We used the administered drugs for 
6 weeks based on the study by van der Donk et al. (24) who found representative 
ingrowth in goats after 6 weeks.
Certainly, our data from this animal study should be interpreted cautiously. Data of  
the effects of  NSAIDs on fixation of  total hip prosthesis in humans are conflicting. 
Ince at al. (11) found no difference in uncemented acetabular component loosening 
after five years when comparing groups which received indomethacin, postoperative 
irradiation or no prophylaxis for heterotopic ossification. Kjaersgaard-Andersen et al. 
(12) also could not detect a difference in loosening or lucensies between patients which 
received Indomethacin and the ones who did not. On the other hand Persson et al. 
(15) found a trend to a higher revision rate in an indomethacin treatment group as 
compared to the patients which didn’t receive any NSAIDs after 10 years follow-up.
Based on our study we conclude that No difference in bone ingrowth could be 
detected with both ketoprofen and meloxicam compared with no medication in 
titanium bone chambers in goats loaded with fresh autograft, allograft or radiated 
allograft. Interpretation to the human situation has to be done carefully, however both 
on these data and clinical data the effect of  NSAIDs on the bone graft ingrowth may 
be limited. 
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Cytokines in drainage fluid after THA
Abstract
Introduction: The reason why heterotopic ossification develops after total hip 
arthroplasty is still not known, but it is assumed that the inflammatory reaction is 
the major driving force. In literature little is known about the cytokine levels at the 
site of  surgery, most measurements are done in serum. This study was conducted to 
investigate if  the levels of  different pro- en anti-inflammatory cytokines are measurable 
in drainage fluid and, when measurable, whether we can find a difference in cytokine 
concentration between one and six hours postoperatively.
Materials and methods: Samples from the drainage system in 30 consecutive 
patients undergoing primary total hip replacement were collected at one and six hours 
after closure of  the wound. GM-CSF, G-CSF, IFN-γ, TNF-α, MCP-1, IL-1β, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13 and MIP-1beta levels were measured 
in the drainage fluids.
Results: Measurable levels of  all cytokines studied were found, except for IL-17. A 
significant elevation of  almost all cytokines was observed between the sample after 
one hour and six hours postoperatively. The elevation was significant for all cytokines 
except IL-10 and MIP-1b.  We found a strong correlation between the different pro-
inflammatory cytokines. Levels are much higher than previously shown levels in 
serum.
Conclusion: Detectable levels of  numerous cytokines can be measured in drainage 
fluid post-operatively. The levels of  most cytokines in drainage fluid are higher in 
samples taken six hours after surgery as compared to samples taken after one hour. 
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Introduction
The incidence of  heterotopic ossification (HO) after primary hip arthroplasty varies 
between 8 and 90 percent in literature (19). The reason why heterotopic ossification 
develops is unknown, but it has been assumed that the inflammatory reaction due to 
the surgical trauma is the major driving force (4). The fact that the incidence of  HO 
in patients receiving non steroidal anti-inflammatory drugs (NSAIDs) after a total hip 
arthroplasty (THA) is much lower as compared to patients not receiving NSAIDs is a 
confirmation of  this assumption (19). 
Multiple cytokines are involved in inflammatory reactions. For one of  the most important 
anti-inflammatory cytokine interleukin 10 (IL-10)  elevated serum levels after trauma 
have been shown (11, 12).  For IL-10 even a positive correlation between higher levels 
immediately after trauma and the occurrence of  sepsis later in the course was reported 
(12).  The main pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) 
and tumor necrosis factor-α (TNF-α) are also involved in the inflammatory response 
after injury (11).  After elective surgery  a temporary elevation of  IL-6 levels in serum 
or plasma has been observed (2, 9, 14, 18, 21, 22, 24, 26). Most reports on the increase 
of  cytokines after trauma or surgery are based on serum levels. There are limited 
data about the cytokine concentrations at the site of  surgery (2, 22, 25). However, as 
cytokines are very effective in cell-to-cell communication (20), the concentration of  
cytokines locally at the surgical site are of  major interest. Furthermore, in most studies 
only the pro inflammatory cytokines are measured, resulting in a lack of  knowledge 
about the elevation of  anti inflammatory cytokines in drainage fluid.
This study was conducted to investigate if  the levels of  different pro- en anti-
inflammatory cytokines are measurable in drainage fluid after total hip arthroplasty 
and whether a difference in cytokine concentration between one and six hours 
postoperatively could be detected. 
Patients and Methods  
From 30 patients operated for a total hip arthroplasty samples from the drainage system 
were collected. All patients were treated according to our local protocol which included 
pre-operative antibiotics (Cefazolin 2 g i.v.) and non steroidal anti inflammatory drugs 
to prevent infection and heterotopic ossification respectively. To facilitate taking 
samples from the standard hip drainage system a three-way connection was used. We 
inserted this connector, which originally is a part from a suprapubic catheter system 
(Cook, Limerick, Ireland) to the drain, on which we placed a three-way connector 
from an intravenous infusion system. A standard collection bag was placed at one end 
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of  the three way system, the other connection was used to collect the samples. In this 
way we were able to take samples from a closed suction drainage system at different 
time intervals instead of  taking samples from the collection bag which would give an 
average of  the time interval the drainage fluid was collected. Samples were taken at 
one and six hours after closure of  the wound. 
After centrifugation of  the fluid at 10.000 for 5 minutes, the supernatant was taken and 
analyzed using the BioPlex™ 17 system (Bio-Rad, Herculus, USA). GM-CSF, G-CSF, 
IFN-γ, TNF-α, MCP-1, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13 
and MIP-1β levels were measured in the drainage fluids, using commercially available 
kits according to the manufacturer’s instructions (Bio-Rad, Hercules, USA). Cytokine 
levels were measured and analyzed using the Bio-Plex system (Bio-Rad, Hercules, 
USA). Data were analyzed using Bio-Plex Manager software. SPSS (Chicago, Illinois) 
version 11.5 was used for data-analysis. The difference between the samples taken 
after one and six hours was compared using the paired sample T-test.
Results
In three of  the 30 patients it was not possible to take samples after one hour, because 
the drain production was too low. In another 8 patients, only one measurement was 
done because the wound drains clotted and stopped draining before the collection at 
six hours. The average drain production after one hour was 55 ml (SD 31 ml), after six 
hours it was 268 ml (SD 134 ml).
We found measurable levels of  all included cytokines except IL-17 in the drainage 
fluid. The cytokine levels are displayed in Table 1. We found a significant elevation of  
almost all cytokines between the samples after one hour and six hours postoperatively. 
The elevation was significant for all cytokines except IL-10 and MIP-1b. Especially 
the elevation of  the concentration in this time interval of  IL- 6 and IL-8 by a factor 
of  31,6 and 49,3 respectively is striking. Calculating the IL-6 to IL-10 ratio, this ratio 
increased from 304 (SD 256) to 12357 (SD 6788) (p<0,000), which shows an increased 
predominance of  the pro-inflammatory cytokines when comparing the measurements 
after one and six hours respectively. We found a strong correlation between the different 
pro-inflammatory cytokines. 
No (negative) correlation between the total drain volume and cytokine level was found, 
so the higher levels of  cytokines are not caused by a concentration effect.
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Discussion
High levels of  numerous cytokines can be detected in drainage fluid after total hip 
arthroplasty. The levels after six hours are higher as compared to one hour after surgery. 
Furthermore the IL-6 to IL-10 ratio is increased between this two measurements, 
suggesting a relative raise in the pro-inflammatory interleukins (23). 
These measured cytokine levels were despite the fact that all patients received NSAIDs 
before surgery to prevent heterotopic ossification, it would have been ideal to compare 
the levels of  cytokines in drainage fluid with patients who do not receive NSAIDs. 
However this was considered unethical due to our local protocol. 
To measure the cytokine levels the BioPlex™ 17 was used, with this system it is 
possible to analyze up to 100 different analytes in a single microtiter well, with a high 
correlation with the traditional ELISA method (6).
As it is almost impossible to measure the interstitial levels of  cytokines, we think the 
levels in drainage fluid are a better representation of  these levels than the levels in 
serum. Although cytokines in general function in cell-to-cell communication (20), not 
at long distances, many studies describe cytokine levels in serum (8, 14, 26, 26). These 
systemic levels could represent either an over- or under representation of  the actual 
interstitial levels (20). Weissflog et al. found a difference in cytokine levels in chest 
tubes, in the same patients they did not detect a difference in the serum levels (25). 
Most studies in which cytokine levels are measured both in drainage fluid and in serum 
show comparable results, the levels in drainage fluid are higher than in serum (1-3, 
13, 22). Furthermore in most studies only the rise in interleukin level in the drainage 
fluid was significant, the levels in serum were not, or only for a subset of  interleukins 
(1, 2, 13, 22). As pro-inflammatory interleukins (mainly TNF-α, IL-1 and IL-6) initiate 
elaboration and release of  other interleukins, anti-inflammatory cytokines (IL4, IL-
10 and IL-13) serve to down regulate synthesis of  pro-inflammatory cytokines (11). 
Taniguchi (23) showed that the ratio of  IL-6 and Il-10 was correlated with injury 
severity after major trauma and it was recommended as a useful marker to predict the 
degree of  injury following trauma. This ratio also seems to be important in elective 
surgery (17). IL-6 levels in serum correlate with disease severity and patient mortality 
in patients with sepsis (5, 10).
Di Vita et al (7) showed that in patients who underwent surgical incisional hernia 
repair the local levels of  cytokines differed between the group in which a mesh was 
used as compared to the group with a direct repair. The group in which a mesh was 
implanted the IL-1 production was higher whereas the direct repair group showed 
higher levels of  IL-1ra and IL-10, which are anti-inflammatory cytokines.
In mice IL-1β stimulates bone formation and IL-1β-antagonist completely abolishes 
bone formation (16). IL-4 and IL-13 induce bone formation and the anti-inflammatory 
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cytokine IL-10 does not induce bone (15). The high levels of  this cytokines found in 
the present study in the drain fluid, whereas these were not measurable in serum in 
former studies, can be a clue to better understanding the pathogenesis of  HO. In 
further research it would be preferable to include a reference group not receiving any 
NSAIDs.
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	 Table	1:	cytokine	concentrations	in	drainage	fluid.
Cytokine	 1	hour	 6	hours	 significance
 Concentration in pg Concentration in pg
IL-2 335 2861 P<0,000
IL-4 5505 45910 P<0.000
IL-6 313914 9916640 P<0,000
IL-8 10615 523257 P<0,000
IL-10 797 1012 P=0,215
IL-1β 498 8126 P<0,000
IL-5 46 197 P<0,000
IL-7 551 965 P<0,000
IL-12 346 1126 P<0,000
IL-13 103 560 P<0,000
GM-CSF 2285 22058 P=0,001
IFN-γ 5477 50363 P<0,000
TNF-α 1241  11559 P<0,000
G-CSF 20200 348667 P<0,000
MCP-1 34086 529352 P<0,000
MIP-1b 19448 16454 P=0,392
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Heterotopic ossification (HO) is formation of  bone where it normally is not present. 
HO can occur following surgical trauma, burns, and neurologic injuries. The 
pathophysiology of  HO is not fully understood. Trauma, however, appears to be 
the main aetiological factor in HO. Whether HO of  body tissues occurs or not, may 
depend on a delicate balance between locally and systemically acting osteogenic and 
osteo-inhibitory factors.
The incidence of  HO after THA among different studies varies between 10 and 90%. 
Larger studies using the same or similar grading systems show considerably smaller 
variations, with HO ranging between 35 and 60%. Severe HO with clinical symptoms, 
such as pain and restricted joint motion leading to functional impairment occurs in 
fewer than 10% of  patients. 
Two different forms of  prophylaxis of  HO are being applied. The first is radiation 
therapy, which can be applied directly before or directly after the operation with 
similar results. The second mode of  prophylaxis is by non-steroidal anti-inflammatory 
drugs (NSAIDs). Dahl (14) was the first to describe the prophylactic effect of  the 
NSAID indomethacin on the incidence of  HO after hip arthroplasty. He observed 
that patients with rheumatoid arthritis developed less HO than osteoarthritis patients, 
and that especially patients who received indomethacin developed less HO. Initially 
the prophylaxis was given for six (12, 56), three and two weeks (35, 41, 47), all with 
similar results. Also other NSAIDs were tested for their prophylactic effects on HO 
and showed similar results (9, 20, 24-26, 54). Even a treatment period of  one week 
appears to be sufficient (51).
Although indomethacin is effective in preventing heterotopic ossification (HO) 
after primary total hip arthroplasty (42, 51), side effects are frequently observed. 
Approximately 30% of  all patients on traditional NSAIDs suffer from gastrointestinal 
side effects; among patients over 65, the incidence of  these side effects is estimated at 
40% (22). 
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The following research questions were formulated:
1  Can the duration of  treatment with indomethacin to prevent HO after 
 THA be shortened?
2  Are the prophylactic effects of  COX-2 selective NSAIDs on the development of  
 HO after THA similar to that of  indomethacin?
3  Do Non-Steroidal Anti-Inflammatory Drugs impair bone ingrowth?
4  Is it possible to measure the local inflammatory response after THA by means 
 of  cytokine levels at the site of  surgery? 
Question 1: Can the duration of  treatment with indomethacin to prevent 
HO after THA be shortened?
In chapter 2 we describe the effects of  a three days indomethacin regimen in a two 
phase study-design. In this design a small group is exposed to the experimental drug 
and only if  the effect in this small group is effective, the study group is expanded. This 
two phase study design (63) was used to limit the number of  patients exposed to a 
potentially inferior treatment. For calculation of  the number of  cases needed in this 
study we used the data of  a patient-group of  our department who did not receive any 
prophylaxis, and data obtained at our department of  a patient group who received 7 
days indomethacin. Given these data a 3 days regimen of  indomethacin is considered 
only effective if  at least 80 % of  the cases will have a Brooker grade 0, 1 or 2. For the 
first phase of  this study 19 cases were necessary. If  these criteria have been fulfilled 
the second phase is started for another 23 patients. In the first phase of  this study 
nineteen patients were included. 14 developed HO (7 grade 1, 4 grade 2 and 3 grade 
3). As compared to the two different historical control groups, the 3 day treatment was 
inferior to the group receiving indomethacin for 7 days. These results did not meet the 
criteria to expand the study group, so the second phase was not started. Dorn et al. (17) 
found a similar higher incidence after a treatment period of  four days as compared to 
the standard treatment of  seven days. We conclude that 3 days indomethacin is not 
effective to prevent heterotopic ossification after THA.
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Question 2: Are the prophylactic effects of  COX-2 selective NSAIDs on 
the development of  HO after THA similar to that of  indomethacin?
In chapter 3 to 6 we describe four studies about more COX-2 selective NSAIDs. From 
a meta-analysis by Neal et al. (51) we know that all traditional NSAIDs except low 
dose aspirin have a similar effect on the prophylaxis of  HO after THA. Traditional 
NSAIDs inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). 
In the eighties and nineties selective COX-2 inhibitors were developed and were 
claimed to provide similar pain reduction with fewer side effects (7, 21, 62) Due to 
this reduction in side effects these COX-2 inhibitors might be attractive to use for 
the prevention of  HO. One of  the first COX-2 preferential NSAIDs was meloxicam. 
In chapter 3 we compared the prophylactic effect of  meloxicam with indomethacin 
and found similar results. Legenstein et al. (45) found the same results as we did, 
only their conclusion was different: because of  the price-difference between the two 
medications, they recommended indomethacin. Barthel (4) found a difference between 
indomethacin and meloxicam in a randomized controlled trial, with a better effect of  
indomethacin. 
In chapter 4 we compared peri-operative blood loss between these two drugs and 
found that the blood loss was 15% lower when meloxicam was used. Therefore our 
recommendation was to use meloxicam. Reduced blood loss after COX-2 selective 
NSAIDs is also described by others (29). 
In chapter 5 a two phase study design was used, which has also been used in chapter 
3 (63, 72). In this study the prophylactic effect of  rofecoxib was compared with the 
standard indomethacin treatment. In the first phase of  this study 4 out of  19 patients 
developed HO (all grade 1). In the second phase 23 patients were included, 4 patients 
developed grade 1 ossification in this second phase. This study showed that the 
prophylactic effect of  rofecoxib is similar to that of  indomethacin. 
Based on these results we started a randomized controlled trial with the intention to 
include 200 patients, however the inclusion of  patients for this study was terminated 
on the day Merck withdrew rofecoxib from the market, i.e. September 30, 2004 (13, 
15). At that time 186 patients were included. Comparing these patients, the incidence 
of  HO was similar in both groups. This study has been discussed in Chaper 6. Grohs 
et al. (32) found similar results although the incidence of  HO was higher in both 
treatment groups, probably because an anterolateral approach was used. With this 
approach a higher incidence can be expected (6, 18). Buvanderan et al. (10) showed 
that patients who received rofecoxib developed less HO as compared to patients not 
receiving NSAIDs after THA. In addition, Banovac et al (3) showed a decrease in HO 
after spinal cord injury when using rofecoxib as compared to no treatment. Based on 
the results from chapter 3 to 6 and the recent literature, it can be concluded that COX-2 
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selective NSAIDs have similar effect on preventing HO as compared to the traditional 
ones.
Question 3: Do Non-Steroidal Anti-Inflammatory drugs impair bone 
ingrowth?
Besides the effects of  COX-2 selective NSAIDs on the cardiovascular system there is 
also rising concern about the effects of  this class of  drugs on fracture repair and bone 
ingrowth in both bone grafts and uncemented prostheses. There is both experimental 
and clinical evidence of  inhibition of  new bone formation by NSAIDs (both selective 
and non-selective) (31, 33, 40, and 64). NSAIDs inhibit bone ingrowth in porous 
implants (31, 33, 68), delay fracture healing (39, 57, 64), inhibit spinal fusion in rats 
(16, 46) and inhibit experimental bone induction (52). Despite the understanding of  
the potential mechanism through which NSAIDs inhibit bone healing in a laboratory 
setting, only few studies exist that show whether these inhibitory effects are also evident 
clinically (33). Clinically, NSAIDs have been found to retard healing of  diaphyseal 
fractures (8) and spinal fusions (30). However, the notion that NSAIDs have serious 
inhibitory effects on bone healing in patients seems hard to accept because millions 
of  people have used these drugs, and an association between nonunion or impaired 
bone healing has not been recognized as a clinical problem (19). Zhang (78) showed 
that restoration of  PGE2 levels in mice immediately rescues the effect of  an absence 
of  COX-2. Thus, withdrawal of  the drug might lead to a restoration of  prostaglandin 
synthesis and a normal bone repair process. 
The effect of  NSAIDs could be even more devastating if  they are combined with 
bone grafts to reconstruct bone defects.  Bone grafts (both autograft and allograft) 
are used in a wide variety of  orthopaedic procedures, such as fracture healing in 
nonunions and spinal fusion, replace traumatic bone loss due to tumor resection or to 
reconstruct deformed joints or failed joint replacements with bone loss. An inhibiting 
effect of  NSAIDs on bone repair could also jeopardize the ingrowth of  these grafts. 
However, we have used NSAIDs (indomethacin for at least 7 days) to prevent HO with 
acetabular reconstructions in both primary and revision hip surgery. The long-term 
clinical results are satisfying, making it hard to believe that NSAIDs have an important 
negative effect on graft incorporation (59, 60, 75). Also in a study on the outcome of  
femoral revision with bone impaction grafting at minimal 10 years the administration 
of  indomethacin did not seem to have had a negative influence on the long-term 
results (58). 
In chapter 7 the effect of  2 different NSAIDs on bone and tissue ingrowth in a bone 
chamber model in goats using autograft, rinsed allograft, and rinsed and subsequently 
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irradiated allograft is described. We used goats in this study, because we think the 
bone metabolism in goats is more comparable with the human bone metabolism, as 
compared to the metabolism in mice or rats in which most other studies have been 
done. Furthermore the pharmacokinetics and pharmacodynamics for goats of  the 
drugs used in this study are known from literature (2, 49, 50, 61, 67). 
The ingrowth itself  in this animal model shows similar ingrowth in rats and goats (71). 
In our study we did not find any difference in bone ingrowth comparing the goats 
treated with either meloxicam or ketoprofen as compared with goats not receiving 
any NSAID. Hofmann et al. (34) describe a study in which they placed titanium and 
tantalum plugs in patients who underwent a staged bilateral total knee arthroplasty 
(TKA). With the implantation of  the first TKA bone plugs were placed which were 
retrieved when the contralateral TKA was inserted after 12 weeks. Patients received 
celecoxib for two weeks and also took fluorochromes to measure the bone ingrowth 
in different time periods. The mineral apposition rate did not show impaired bone 
ingrowth during the treatment period with celecoxib. Ince et al.(37) showed in a 
prospective study that no difference was found in uncemented acetabular component 
loosening comparing patients receiving irradiation (n=106) or indomethacin (n=98) as 
prophylaxis for HO as compared to control patients (n=82). Wurnig et al. (76) found 
comparable results six years after uncemented THA implantation in two groups, one 
receiving indomethacin, the other not receiving any NSAID. So the effect of  NSAIDs 
on bone ingrowth seems to be limited.
Question 4: Is it possible to measure the local inflammatory response 
after THA by means of  cytokine levels at the site of  surgery?
The main contributing factor in the development of  HO seems to be trauma and the 
inflammatory response to this trauma. This appears to be the case in brain or spinal 
cord injury in multi-traumatized patients, as well as in the event of  local tissue trauma 
after surgery. Multiple cytokines are involved in inflammatory reactions. The main 
pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor 
necrosis factor-α (TNF-α) are involved in the inflammatory response after injury (27). 
After elective surgery  a temporary elevation of  IL-6 levels in serum or plasma has 
been observed (1, 23, 44, 48, 55, 65, 73, 77). For one of  the most important anti-
inflammatory cytokines interleukin 10 (IL-10) elevated serum levels after trauma have 
been shown (27, 28). For IL-10 a positive correlation between higher levels immediately 
after trauma and the occurrence of  sepsis later in the course of  the disease has been 
reported (28). The IL-6/IL-10 ratio can be used as a measure for the severity of  
trauma (66). Most reports on the increase of  cytokines after trauma or surgery are 
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based on serum levels. There are limited data about the cytokine concentrations at the 
site of  surgery (1, 36, 43, 65, 74). However, as cytokines are very effective in cell-to-cell 
communication (53), the concentration of  cytokines locally at the surgical site is of  
major interest. As it is almost impossible to measure the interstitial levels of  cytokines, 
we think the levels in drainage fluid are a better representation of  these levels than the 
levels in serum. Furthermore, in most studies only the pro-inflammatory cytokines are 
measured, resulting in a lack of  knowledge about the elevation of  anti-inflammatory 
cytokines in drainage fluid. 
In chapter 8 a pilot study is described in which drain fluid was collected and analysed 
1 and 6 hours postoperative. A large increase of  the pro-inflammatory cytokines, 
and also of  the IL-6/ IL-10 ratio was found, suggesting a predominance of  the pro 
inflammatory cytokines.
It would be interesting to compare these values between patients receiving NSAIDs 
and patients not receiving any of  these drugs. However, due to the local protocol 
in which all patients getting a THA receive an NSAID in our hospital this is not 
possible. Buvanendran (11) compared levels of  different cytokines and prostaglandins 
in drainage fluid (and cerebrospinal fluid) and found elevated levels of  both PGs and 
ILs in patients not receiving NSAIDs compared to patients taking rofecoxib. The 
levels they found were taken at different time-intervals as compared to our study 
making comparison difficult; furthermore they only measured the pro-inflammatory 
cytokines.
From the pilot study described in chapter 8 it becomes clear that it is possible to measure 
the elevated levels of  different cytokines after 6 hours as compared to 1 hour post 
operatively. 
Conclusions:
1 Three days indomethacin as prophylaxis for HO after THA is less effective 
 as compared to indomethacin for seven days.
2 COX-2 selective NSAIDs have similar prophylactic effects on HO after 
 primary THA as compared to the traditional NSAIDs. 
3 The effect of  NSAIDs on bone ingrowth seems to be limited.
4 The local inflammatory response after a THA, measured in drainage fluid, 
 shows a predominance of  pro inflammatory cytokines
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Closing remarks and suggestions for further research
HO after THA is a complication which occurs in about 50% of  cases. With prophylactic 
treatment by means of  non-steroidal anti-inflammatory drugs the incidence of  this 
ossification can be reduced. The shortest effective treatment period seems to be one 
week. When comparing traditional NSAIDs with COX-2 selective ones the results 
are comparable. COX-2 selective NSAIDs give an increased cardiovascular risk 
when used for more than 18 months, while short term use have not been associated 
with an increased risk. However, this relatively new class of  drugs has not been fully 
investigated with postoperative use.
Data on bone ingrowth and fracture repair are conflicting. From clinical experience it 
is hard to believe that NSAIDs would have a large impact on fracture repair as most 
trauma patients receive NSAIDs in daily practice. Fracture healing could be compared 
in patients taking NSAIDs and patients not receiving any of  these drugs. In former 
studies this comparison has been made, but most studies have methodological flaws. 
Especially in retrospective studies in which no NSAIDs were prescribed or mentioned 
in the medical record, will not necessarily mean patients didn’t take these drugs, as 
these drugs can be bought over the counter (without prescription). Furthermore, 
exposure to NSAIDs in the period 61-90 days after a fracture has been associated with 
nonunion (5). Although this association may be causal, it is more likely to reflect the 
use of  analgesics by patients with painful non healing fractures.
Treatment for common fractures, like distal radius fractures could be compared in a 
placebo controlled randomized trial with different NSAIDs. As Union after an osteotomy 
could also be jeopardized by NSAIDs, an other possibility is to compare patients with 
an osteotomy in a comparative study with and without NSAIDs. As bone ingrowth is 
also necessary in fixation of  uncemented total hip arthroplasty, further research could 
also be done in patients receiving an uncemented hip prosthesis. As plain radiography 
is not reliable to investigate whether a prosthesis is well fixed or not, two other outcome 
measures could be used. First we can compare the revision rate of  these implants in 
patients who used NSAIDs and patients who did not. However, the revision rate of  
THA is estimated to be about 10% after 10 years, so we would need a large cohort and 
a long follow-up. The second possibility is to compare patients receiving NSAIDs with 
placebo-treated patients with Roentgen Stereophotogrammetric Analysis (RSA). With 
this validated method it is possible to detect movements of  the prosthesis (which can 
be indicative for loosening) in a reliable way (38, 69, 70). An advantage of  this method 
would be that a much smaller amount of  patients and a shorter follow-up time are 
needed to detect a difference in loosening of  the prosthesis.
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To elucidate more about the inflammatory reaction at the surgical site comparisons 
could be made between levels of  different cytokines in drainage fluid, comparing 
patients using NSAIDs with patients not receiving any of  these drugs. As the 
inflammatory response changes over time it would be interesting to measure the levels 
of  different cytokines at different time intervals. Furthermore it would be interesting 
to investigate the possible relationship between the measured inflammatory response 
and the severity of  heterotopic ossification. 
114
Summary and general discussion
Reference List
1.  Andres BM, Taub DD, Gurkan I, Wenz JF. Postoperative fever after total knee arthroplasty: the role of  cytokines.  
 Clin Orthop 415: 221-31, 2003.
2.  Arifah AK, Landoni MF, Lees P. Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of    
 ketoprofen in the goat. J Vet Pharmacol Ther 26: 139-50, 2003.
3.  Banovac K, Williams JM, Patrick LD, Levi A. Prevention of  heterotopic ossification after spinal cord injury with  
 COX-2 selective inhibitor (rofecoxib). Spinal Cord 42: 707-10, 2004.
4.  Barthel T, Baumann B, Noth U, Eulert J. Prophylaxis of  heterotopic ossification after total hip arthroplasty: 
 a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 73: 611-4, 2002.
5.  Bhattacharyya T, Levin R, Vrahas MS, Solomon DH. Nonsteroidal antiinflammatory drugs and nonunion of   
 humeral shaft fractures. Arthritis Rheum 53: 364-7, 2005.
6.  Bischoff  R, Dunlap J, Carpenter L, DeMouy E, Barrack R. Heterotopic ossification following uncemented total  
 hip arthroplasty. Effect of  the operative approach. J Arthroplasty 9: 641-4, 1994.
7.  Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ,   
 Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of  upper gastrointestinal toxicity of  rofecoxib and naproxen  
 in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-8, 2, 2000.
8.  Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of   
 long-bone nonunion. J Bone Joint Surg Br 85: 700-5, 2003.
9.  Burssens A, Thiery J, Kohl P, Molderez A, Haazen L. Prevention of  heterotopic ossification with tenoxicam   
 following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. 
 Acta Orthop Belg 61: 205-11, 1995.
10.  Buvanendran A, Kroin JS, Berger RA. Preoperative cyclooxygenase-2 inhibitor treatment reduces the incidence 
 of  heterotopic ossification after hip arthroplasty: six-month follow-up. Anesthesiology 107: 358-9, 2007.
11.  Buvanendran A, Kroin JS, Berger RA, Hallab NJ, Saha C, Negrescu C, Moric M, Caicedo MS, Tuman KJ.   
 Upregulation of  prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and  
 after surgery in humans. Anesthesiology 104: 403-10, 2006.
12.  Cella JP, Salvati EA, Sculco TP. Indomethacin for the prevention of  heterotopic ossification following total hip  
 arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 3: 229-34, 1988.
13.  Couzin J. Drug safety. Withdrawal of  Vioxx casts a shadow over COX-2 inhibitors. Science 306: 384-5, 2004.
14.  Dahl HK. Kliniske observasjoner. Symposium on hip arthrose Blindern, MSD, Norway 37-46, 1975.
15.  Dieppe PA, Ebrahim S, Martin RM, Juni P. Lessons from the withdrawal of  rofecoxib. BMJ 329: 867-8, 2004.
16.  Dimar JR, Ante WA, Zhang YP, Glassman SD. The effects of  nonsteroidal anti-inflammatory drugs on posterior  
 spinal fusions in the rat. Spine 21: 1870-6, 1996.
17.  Dorn U, Grethen C, Effenberger H, Berka H, Ramsauer T, Drekonja T. Indomethacin for prevention of    
 heterotopic ossification after hip arthroplasty. A randomized comparison between 4 and 8 days of  treatment. 
 Acta Orthop Scand 69: 107-10, 1998.
18.  Eggli S, Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. 
 Arch Orthop Trauma Surg 121: 531-5, 2001.
19.  Einhorn TA. Do inhibitors of  cyclooxygenase-2 impair bone healing? J Bone Miner Res 17: 977-8, 2002.
20.  Elmstedt E, Lindholm TS, Nilsson OS, Tornkvist H. Effect of  ibuprofen on heterotopic ossification after hip   
 replacement. Acta Orthop Scand 56: 25-7, 1985.
21.  Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of  traditional   
 nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 132: 134-43, 2000.
22.  Fijn R, Koorevaar RT, Brouwers JR. Prevention of  heterotopic ossification after total hip replacement with   
 NSAIDs. Pharm World Sci 25: 138-45, 2003.
23.  Frank SM, Kluger MJ, Kunkel SL. Elevated thermostatic setpoint in postoperative patients. 
 Anesthesiology 93: 1426-31, 2000.
24.  Gebuhr P, Sletgard J, Dalsgard J, Soelberg M, Keisu K, Hanninen A, Crawford M. Heterotopic ossification after  
 hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips. 
 Acta Orthop Scand 67: 29-32, 1996.
25.  Gebuhr P, Soelberg M, Orsnes T, Wilbek H. Naproxen prevention of  heterotopic ossification after hip arthroplasty.  
 A prospective control study of  55 patients. Acta Orthop Scand 62: 226-9, 1991.
26.  Gebuhr P, Wilbek H, Soelberg M. Naproxen for 8 days can prevent heterotopic ossification after hip arthroplasty.  
 Clin Orthop 314: 166-9, 1995.
27.  Giannoudis PV. Current concepts of  the inflammatory response after major trauma: an update. 
 Injury 34: 397-404, 2003.
28.  Giannoudis PV, Smith RM, Perry SL, Windsor AJ, Dickson RA, Bellamy MC. Immediate IL-10 expression   
 following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development 
 of  sepsis. Intensive Care Med 26: 1076-81, 2000.
29.  Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in postoperative pain management: current evidence 
 and future directions. Anesthesiology 99: 1198-208, 2003.
30.  Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of  postoperative nonsteroidal  
 anti-inflammatory drug administration on spinal fusion. Spine 23: 834-8, 1998.
115
9
C
hapter
31.  Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL.  
 COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 20: 1164-9, 2002.
32.  Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of   
 heterotopic ossification after hip replacement. A double-blind randomized trial of  100 patients with 1-year 
 follow up. Acta Orthop 78: 95-8, 2006.
33.  Harder AT, An YH. The mechanisms of  the inhibitory effects of  nonsteroidal anti-inflammatory drugs on bone  
 healing: a concise review. J Clin Pharmacol 43: 807-15, 2003.
34.  Hofmann AA, Bloebaum RD, Koller KE, Lahav A. Does celecoxib have an adverse effect on bone remodeling 
 and ingrowth in humans? Clin Orthop Relat Res 452: 200-4, 2006.
35.  Hofmann S, Trnka HJ, Metzenroth H, Frank E, Ritschl P, Salzer M. General short-term indomethacin prophylaxis  
 to prevent heterotopic ossification in total hip arthroplasty. Orthopedics 22: 207-11, 1999.
36.  Holzheimer RG, Steinmetz W. Local and systemic concentrations of  pro- and anti-inflammatory cytokines in  
 human wounds. Eur J Med Res 5: 347-55, 2000.
37.  Ince A, Sauer U, Wollmerstedt N, Hendrich C. No Migration of  Acetabular Cups After Prophylaxis for   
 Heterotopic Ossification. Clin Orthop Relat Res 461: 125-9, 2007.
38.  Kaptein BL, Valstar ER, Stoel BC, Reiber HC, Nelissen RG. Clinical validation of  model-based RSA for a 
 total knee prosthesis. Clin Orthop Relat Res 464: 205-9, 2007.
39.  Keller J, Bunger C, Andreassen TT, Bak B, Lucht U. Bone repair inhibited by indomethacin. 
 Effects on bone metabolism and strength of  rabbit osteotomies. Acta Orthop Scand 58: 379-83, 1987.
40.  Keller JC, Trancik TM, Young FA, St Mary E. Effects of  indomethacin on bone ingrowth.
  J Orthop Res 7: 28-34, 1989.
41.  Kjaersgaard-Andersen P, Nafei A, Teichert G, Kristensen O, Schmidt SA, Keller J, Lucht U. Indomethacin for  
 prevention of  heterotopic ossification. A randomized controlled study in 41 hip arthroplasties. 
 Acta Orthop Scand 64: 639-42, 1993.
42.  Knelles D, Barthel T, Karrer A, Kraus U, Eulert J, Kolbl O. Prevention of  heterotopic ossification after total hip  
 replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose  
 irradiation. J Bone Joint Surg Br 79: 596-602, 1997.
43.  Kristiansson M, Soop M, Sundqvist KG, Soop A, Suontaka AM, Blomback M. Local vs. systemic immune and  
 haemostatic response to hip arthroplasty. Eur J Anaesthesiol 15: 260-70, 1998.
44.  Lahat N, Zlotnick AY, Shtiller R, Bar I, Merin G. Serum levels of  IL-1, IL-6 and tumour necrosis factors in patients  
 undergoing coronary artery bypass grafts or cholecystectomy. Clin Exp Immunol 89: 255-60, 1992.
45.  Legenstein R, Bosch P, Ungersbock A. Indomethacin versus meloxicam for prevention of  heterotopic ossification  
 after total hip arthroplasty. Arch Orthop Trauma Surg 123: 91-4, 2003.
46.  Martin GJ, Jr., Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory  
 effect of  ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse   
 process spine fusion. Spine 24: 2188-93, 1999.
47.  McMahon JS, Waddell JP, Morton J. Effect of  short-course indomethacin on heterotopic bone formation after  
 uncemented total hip arthroplasty. J Arthroplasty 6: 259-64, 1991.
48.  Miyawaki T, Maeda S, Koyama Y, Fukuoka R, Shimada M. Elevation of  plasma interleukin-6 level is involved in  
 postoperative fever following major oral and maxillofacial surgery. 
 Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 146-52, 1998.
49.  Moses VS, Bertone AL. Nonsteroidal anti-inflammatory drugs. 
 Vet Clin North Am Equine Pract 18: 21-37, v, 2002.
50.  Musser JM, Anderson KL, Tyczkowska KL. Pharmacokinetic parameters and milk concentrations of  ketoprofen  
 after administration as a single intravenous bolus dose to lactating goats. J Vet Pharmacol Ther 21: 358-63, 1998.
51.  Neal BC, Rodgers A, Clark T, Gray H, Reid IR, Dunn L, MacMahon SW. A systematic survey of  13 randomized  
 trials of  non-steroidal anti-inflammatory drugs for the prevention of  heterotopic bone formation after major hip  
 surgery. Acta Orthop Scand 71: 122-8, 2000.
52.  Persson PE, Sisask G, Nilsson O. Indomethacin inhibits bone formation in inductive allografts but not in autografts:  
 studies in rat. Acta Orthop 76: 465-9, 2005.
53.  Porter JM. Cytokines and pleural drainage fluid: do local levels make a difference? Chest 115: 1489-90, 1999.
54.  Pritchett JW. Ketorolac prophylaxis against heterotopic ossification after hip replacement. 
 Clin Orthop 314: 162-5, 1995.
55.  Pullicino EA, Carli F, Poole S, Rafferty B, Malik ST, Elia M. The relationship between the circulating   
 concentrations of  interleukin 6 (IL-6), tumor necrosis factor (TNF) and the acute phase response to elective surgery  
 and accidental injury. Lymphokine Res 9: 231-8, 1990.
56.  Ritter MA, Gioe TJ. The effect of  indomethacin on para-articular ectopic ossification following total hip   
 arthroplasty. Clin Orthop 167: 113-7, 1982.
57.  Ro J, Sudmann E, Marton PF. Effect of  indomethacin on fracture healing in rats. 
 Acta Orthop Scand 47: 588-99, 1976.
58.  Schreurs BW, Arts JJ, Verdonschot N, Buma P, Slooff  TJ, Gardeniers JW. Femoral component revision with use of   
 impaction bone-grafting and a cemented polished stem. J Bone Joint Surg Am 87: 2499-507, 2005.
116
Summary and general discussion
59.  Schreurs BW, Bolder SB, Gardeniers JW, Verdonschot N, Slooff  TJ, Veth RP. Acetabular revision with impacted  
 morsellised cancellous bone grafting and a cemented cup. A 15- to 20-year follow-up. 
 J Bone Joint Surg Br 86: 492-7, 2004.
60.  Schreurs BW, Busch VJ, Welten ML, Verdonschot N, Slooff  TJ, Gardeniers JW. Acetabular reconstruction with  
 impaction bone-grafting and a cemented cup in patients younger than fifty years old. 
 J Bone Joint Surg Am 86-A: 2385-92, 2004.
61.  Sidhu P, Shojaee AF, Andrews M, Lees P. Tissue chamber model of  acute inflammation in farm animal species.  
 Res Vet Sci 74: 67-77, 2003.
62.  Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, 
 Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with  
 celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: 
 A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-55, 2000.
63.  Simon R. Optimal two stage designs for phase ll clinical trials. control clin trials 10: 1, 1989.
64.  Simon AM, O’Connor JP. Dose and time-dependent effects of  cyclooxygenase-2 inhibition on fracture-healing. 
 J Bone Joint Surg Am 89: 500-11, 2007.
65.  Southern EP, Huo MH, Mehta JR, Keggi KJ. Unwashed wound drainage blood. What are we giving our patients?  
 Clin Orthop 320: 235-46, 1995.
66.  Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. The ratio of  interleukin-6 to interleukin-10  
 correlates with severity in patients with chest and abdominal trauma. Am J Emerg Med 17: 548-51, 1999.
67.  Taylor PM. Newer analgesics. Nonsteroid anti-inflammatory drugs, opioids, and combinations. 
 Vet Clin North Am Small Anim Pract 29: 719-35, vii, 1999.
68.  Trancik T, Mills W, Vinson N. The effect of  indomethacin, aspirin, and ibuprofen on bone ingrowth into a 
 porous-coated implant. Clin Orthop 249: 113-21, 1989.
69.  Valstar ER, Gill R, Ryd L, Flivik G, Borlin N, Karrholm J. Guidelines for standardization of  radiostereometry  
 (RSA) of  implants. Acta Orthop 76: 563-72, 2005.
70.  Valstar ER, Vrooman HA, Toksvig-Larsen S, Ryd L, Nelissen RG. Digital automated RSA compared to manually  
 operated RSA. J Biomech 33: 1593-9, 2000.
71.  van der Donk S, Buma P, Aspenberg P, Schreurs BW. Similarity of  bone ingrowth in rats and goats: 
 a bone chamber study. Comp Med 51: 336-40, 2001.
72.  van der Heide HJ, Koorevaar RT, Schreurs BW, van Kampen A, Lemmens A. Indomethacin for 3 days is not  
 effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. 
 J Arthroplasty 14: 796-9, 1999.
73.  van Deuren M, Twickler TB, Waal Malefyt MC, Van Beem H, van d, V, Verschueren CM, van der Meer JW.  
 Elective orthopedic surgery, a model for the study of  cytokine activation and regulation. 
 Cytokine 10: 897-903, 1998.
74.  Weissflog D, Kroegel C, Luttmann W, Grahmann PR, Hasse J. Leukocyte infiltration and secretion of  cytokines 
 in pleural drainage fluid after thoracic surgery: impaired cytokine response in malignancy and postoperative   
 complications. Chest 115: 1604-10, 1999.
75.  Welten ML, Schreurs BW, Buma P, Verdonschot N, Slooff  TJ. Acetabular reconstruction with impacted   
 morcellized cancellous bone autograft and cemented primary total hip arthroplasty: a 10- to 17-year follow-up  
 study. J Arthroplasty 15: 819-24, 2000.
76.  Wurnig C, Schwameis E, Bitzan P, Kainberger F. Six-year results of  a cementless stem with prophylaxis against  
 heterotopic bone. Clin Orthop 361: 150-8, 1999.
77.  Yamauchi H, Kobayashi E, Yoshida T, Kiyozaki H, Hozumi Y, Kohiyama R, Suminaga Y, Sakurabayashi I,   
 Fujimura A, Miyata M. Changes in immune-endocrine response after surgery. Cytokine 10: 549-54, 1998.
78.  Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O’Keefe RJ. Cyclooxygenase-2 regulates mesenchymal  
 cell differentiation into the osteoblast lineage and is critically involved in bone repair. 
 J Clin Invest 109: 1405-15, 2002.


Summary and General 
discussion in Dutch
Nederlandse samenvatting en 
algemene discussie
Chapter 10
120
Nederlandse samenvatting
Het plaatsen van een totale heupprothese is binnen de orthopedie een van de meest 
dankbare operaties. Zoals bij alle operaties kan er ook na het plaatsen van een 
heupprothese een aantal complicaties ontstaan. Als belangrijkste zijn dat infecties, 
luxaties en het ontstaan van Heterotope (ofwel peri-articulaire) ossificatie (HO). 
Heterotope ossificatie is het vormen van bot buiten het skelet (56). De pathophysiology 
van HO is niet geheel duidelijk, maar trauma lijkt een belangrijke gezamenlijke factor 
te zijn bij de verschillende oorzaken. Of  HO vormt is afhankelijk van een fijne balans 
tussen osteo-inductieve en osteo-inhiberende factoren die zowel lokaal als systemisch 
van invloed kunnen zijn. HO komt vooral voor na (neuro) trauma, brandwonden 
en na het plaatsen van een heupprothese. De mildere vormen van ossificatie geven 
geen klachten, waarbij de diagnose alleen op de röntgenfoto wordt gesteld. Ernstigere 
vormen kunnen bewegingsbeperking en pijn geven. 
Het vóórkomen van HO wordt in de literatuur nogal wisselend beschreven en wisselt 
tussen de 10 en 90%. In grotere studies worden percentages tussen de 35 en 60 
gevonden. Symptomatische ossificatie treedt in minder dan 10%  van de heupprotheses 
op. 
Er zijn twee verschillende profylaxes die gebruikt worden ter voorkoming van HO. 
Ten eerste is dat radiotherapie, die zowel pré- als postoperatief  gegeven kan worden 
met hetzelfde resultaat. De tweede vorm van profylaxe is middels NSAIDs (Non-
Steroidal Anti-Inflammatory Drugs). Dahl (14) was de eerste die het profylactische 
effect van indomethacine beschreef. Hij merkte dat zijn reumapatiënten minder HO 
ontwikkelden dan de artrose patiënten, en vooral de patiënten die indomethacine 
hadden gekregen. Aanvankelijk werd de profylaxe voor 6 weken gegeven (12, 57), 
later voor 2 en 3 weken (35, 41, 47) en zelfs een periode van een week bleek voldoende 
(51). Ook andere NSAIDs hebben een vergelijkbaar profylactisch effect op HO (9, 20, 
24-26, 54).
De effectiviteit van Indomethacine voor minimaal 1 week ter voorkoming van HO is 
bekend (42, 51), echter deze profylaxe geeft veel bijwerkingen, voornamelijk gastro-
intestinaal. Ongeveer 30% van de patiënten die NSAIDs gebruiken krijgt bijwerkingen 
en bij de patiënten boven de 65 is dit percentage zelfs 40 (22).
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De belangrijkste onderzoeksvragen die aan het begin van dit proefschrift gesteld zijn 
waren:
1  Kan de duur van de profylaxe met indomethacine worden verkort?
2  Hebben COX-2 selectieve NSAIDs een profylactisch effect op HO    
 vergelijkbaar met indomethacine?
3  Remmen NSAIDs bot ingroei?
4  Kunnen we de inflammatoire respons na het plaatsen van een THA   
meten, door de cytokine concentraties uit de wond te bepalen?
Vraag 1: Kan de duur van de profylaxe met indomethacine worden 
verkort?
In hoofdstuk 2  staat een studie naar het effect van Indomethacine voor drie dagen 
in een 2-fasen studieopzet. In deze opzet krijgt eerst een beperkt aantal patiënten 
de experimentele behandeling, deze onderzoeksgroep wordt allen uitgebreid bij het 
voldoen aan van te voren vastgestelde criteria. Er is voor deze onderzoeksopzet (64) 
gekozen om zo weinig mogelijk patiënten bloot te stellen aan een mogelijk inferieure 
therapie. De grootte van de studiegroep hebben we berekend door te kijken naar twee 
historische groepen van onze afdeling. De eerste groep had geen NSAIDs als profylaxe 
gekregen, de andere groep had 1 week indomethacine 3 x 50 mg per dag gekregen. 
Gebaseerd op de incidentie van HO in beide controlegroepen zijn we er van uit gegaan 
dat de incidentie van graad 0, 1 en 2 samen in de experimentele groep tenminste 80% 
moest zijn. Van de 19 patiënten uit dit onderzoek ontwikkelden er 14 HO (7 graad 
1,4 graad 2 en 3 graad 3), hierdoor werd niet voldaan aan de vooropgestelde criteria 
en werd de tweede fase van de studie niet gestart. Dorn et al. (17) bevestigden deze 
resultaten in een groep patiënten die 4 dagen indomethacine kregen. Ook in die studie 
was 7 dagen indomethacine duidelijk superieur aan de experimentele periode van 4 
dagen. Concluderend: de profylactische behandeling met indomethacine voor drie 
dagen is niet zinvol.
Vraag 2: Hebben COX-2 selectieve NSAIDs een profylactisch effect op 
HO vergelijkbaar met indomethacine?
In hoofdstuk 3 tot en met 6 staan 4 studies die het profylactische effect van (meer) COX-2 
selectieve middelen beschrijven. Van de meta-analyse van Neal et al. (51) weten we 
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dat eigenlijk alle conventionele NSAIDs (uitgezonderd lage dosering acetylsalicylzuur) 
een vergelijkbaar profylactisch effect hebben op het ontstaan van HO na THA. 
Traditionele NSAIDs remmen zowel cyclooxygenase-1 (COX-1) als cyclooxogenase-2 
(COX-2). In de jaren tachtig en negentig zijn er verschillende COX-2 selectieve 
middelen ontwikkeld. Deze middelen geven een vergelijkbaar pijnstillend effect met 
minder bijwerkingen (7, 21, 63). Door deze reductie van het aantal en de ernst van 
de bijwerkingen zouden deze middelen een aantrekkelijk alternatief  kunnen zijn 
voor de klassieke NSAIDs als HO-profylaxe. Een van de eerste COX-2 preferentiële 
NSAIDs was meloxicam. In Hoofdstuk 3 staat een vergelijkende studie beschreven 
waarbij meloxicam wordt vergeleken met de standaardbehandeling bestaande uit 
indomethacine voor 7 dagen. De conclusie van deze studie is dat het profylactische 
effect van meloxicam vergelijkbaar is met dat van indomethacine. Legenstein et al. (45) 
vonden hetzelfde resultaat, alleen was hun conclusie anders. Zij adviseren gezien het 
prijsverschil om het klassieke middel indomethacine te geven. Barthel et al. (4) vonden 
een beter profylactisch effect van indomethacine in vergelijking met meloxicam. 
In hoofdstuk 4 wordt het verschil in peri-operatief  bloedverlies beschreven tussen de 
twee onderzoeksgroepen uit hoofdstuk 3. In de meloxicam groep was het bloedverlies 
15% lager dan in de indomethacine groep. Ook anderen hebben deze reductie in 
peri-operatief  bloedverlies bij het gebruik van COX-2 selectieve middelen beschreven 
(29). De combinatie van hoofdstuk 3 en 4 heeft geleid tot de conclusie dat er een 
voorkeur bestaat voor behandeling met meloxicam, aangezien het profylactische effect 
ten aanzien van HO gelijk is en het peri-operatieve bloedverlies lager.
In hoofdstuk 5 is dezelfde onderzoeksopzet gebruikt als in hoofdstuk 3 (64, 73) waarbij 
ditmaal het effect van rofecoxib werd vergeleken met dezelfde twee historische 
referentiegroepen. In tegenstelling tot de resultaten in hoofdstuk 3 bleek er nu wel een 
effect te zijn in de eerste fase. Van de 19 patiënten ontwikkelden er 4 een graad 1 
ossificatie. Hierna werd de tweede fase gestart waarin 23 patiënten werden geïncludeerd. 
Ook in de tweede fase ontwikkelden 4 patiënten een graad 1 HO. De conclusie van 
deze studie was derhalve dat het effect van 7 dagen rofecoxib vergelijkbaar is met 
dat van 7 dagen indomethacine. Om deze onderzoeksresultaten te bevestigen werd 
een Randomized Controlled Trial (RCT) opgezet waarbij de intentie bestond om 2 x 
100 patiënten te includeren, 100 in de indomethacine groep en 100 in de rofecoxib 
groep. Echter door de cardiovasculaire bijwerkingen die werden geconstateerd na 
langdurig gebruik van rofecoxib werd dit middel door Merck op 30 september 2004 
van de markt gehaald (13, 15). Ondertussen waren er 186 patiënten geïncludeerd, de 
resultaten van de profylactische behandeling van deze patiënten is vergelijkbaar tussen 
de twee groepen, deze resultaten staan beschreven in hoofdstuk 6.
Grohs et al. (32) vonden dezelfde resultaten alleen kwamen er meer HO in beide 
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onderzoeksgroepen in hun studie, waarschijnlijk wordt dit veroorzaakt doordat in die 
studie gebruik werd gemaakt van een anterolaterale benadering van het heupgewricht, 
een benadering waarbij de incidentie van HO hoger is (6, 18). Buvanderan et al. (10) 
hebben twee groepen vergeleken na een THA, de eerste groep kreeg rofecoxib, de 
andere groep kreeg geen profylaxe. In de rofecoxib kwam minder HO voor dan in de 
groep die geen profylaxe kreeg.
Banovac et al (3) lieten een daling van het aantal HO zien na behandeling met 
rofecoxib na neurologisch letsel in vergelijking met de patiënten die geen profylaxe 
kregen. Concluderend kunnen we stellen dat het profylactische effect (voor HO) van 
COX-2 selectieve middelen en indomethacine vergelijkbaar is.
Vraag 3: Remmen NSAIDs bot ingroei?
Naast het verhoogde cardiovasculaire risico bij gebruik van COX-2 selectieve 
middelen, komen er ook meer aanwijzingen dat deze middelen een negatief  effect 
hebben op de fractuurgenezing. Er is zowel experimenteel als klinisch bewijs dat 
NSAIDs (zowel selectieve als niet selectieve) botvorming kunnen remmen (31, 33, 
40, 65). NSAIDs remmen bot ingroei in poreuze implantaten (31, 33, 69), vertragen 
fractuur genezing (39, 58, 65), vertragen fusie na spondylodese in ratten (16, 46) en 
inhiberen experimentele bot inductie (52). Ondanks de aanwijzingen dat NSAIDs 
botgroei remmen in een laboratorium, zijn er maar weinig studies die dit effect ook 
klinisch aantonen (33). Twee belangrijke klinische studies betreffen een vertraagde 
genezing van diafysaire fracturen in multitrauma patiënten die voor hun operatief  
behandelde acetabulum fractuur gerandomiseerd wel of  geen indomethacine kregen 
(8). In de indomethacine groep kwamen beduidend meer pseudarthroses voor dan in 
de placebo groep. Een andere studie beschrijft de verhoogde kans op pseudarthrose 
na een spondylodese (30). Ondanks deze aanwijzingen dat NSAIDs bot groei remmen 
is het moeilijk aan te nemen dat in een klinische setting het negatieve effect groot is. 
Miljoenen patiënten over de hele wereld gebruiken NSAIDs na een fractuur en de 
associatie tussen het gebruik van deze medicatie en vertraagde fractuurgenezing is 
geen duidelijk klinisch probleem (19). Zhang (79) liet zien dat een verhoging van PGE2 
de afwezigheid van COX-2 herstelt. Het zou kunnen zijn dat er en herstel optreedt 
van de fractuurgenezing na het stoppen van de NSAIDs omdat er een herstel optreedt 
van de PGE2 synthese. 
Het negatieve effect van NSAIDs op botgroei kan nog erger zijn als ze gecombineerd 
worden met een botgraft. Botgrafts (zowel autografts als allografts) worden in veel 
verschillende procedures gebruikt, zoals fractuur behandeling, behandeling van non-
unions, spondylodese, maar ook bij grotere botdefecten zoals bij oncologische resecties 
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en prothese revisies. Een remmend effect van NSAIDS zou dus ook de incorporatie 
van deze grafts nadelig kunnen beïnvloeden. Echter, op de afdeling orthopedie van 
het RUNMC wordt al jaren een botgraft techniek gebruikt voor heuprevisies waarbij 
alle patiënten ook minimaal 7 dagen indomethacine kregen als HO-profylaxe. De 
resultaten van de geïmpacteerde botgrafts laten voor zowel acetabulaire (60, 61, 76) 
als femorale (59) reconstructies goede lange termijn resultaten zien, zodat het moeilijk 
is om aan te nemen dat NSAIDs een belangrijk effect op graft incorporatie in de mens 
hebben. 
In hoofdstuk 7 wordt een botkamer studie beschreven waarin het effect van NSAIDs op 
bot ingroei in titanium botkamers in de geit werd onderzocht. In de meeste andere 
dierexperimentele studies naar het effect van NSAIDs op bot ingroei is gebruik gemaakt 
van ratten of  konijnen. Om twee redenen hebben we gekozen om in dit experiment 
gebruik te maken van geitenstudie. Ten eerste is de farmacokinetiek en dynamiek van 
verschillende NSAIDs bekend voor de geit (2, 49, 50, 62, 68), ten tweede verwachten 
we dat het botmetabolisme van de mens meer vergelijkbaar is met dat van de geit 
dan dat van de rat. De ingroei van bot in dit botkamermodel in de geit is bekend en 
is vergelijkbaar met dat in de rat (72) In het experiment werden 3 botkamers geplaats 
in de beide proximale tibiae van volwassen geiten. Deze 3 kamers warden gevuld 
met autograft, allograft en bestraalde allograft. De geiten warden verdeeld over drie 
groepen, waarbij de eerste groep geen NSAIDs kreeg, de tweede groep ketoprofen 
(een niet selectief  NSAID) en de derde groep meloxicam (een COX-2 preferentieel 
middel). In deze experimentele studie werd geen verschil in botingroei gezien tussen 
de verschillende medicatie.
Hofmann et al. (34) beschrijven een groep patiënten die een bilaterale totale 
knieprothese kregen in 2 tempi met een interval van 12 weken. Bij het plaatsen van de 
eerste TKA werden titanium en tantalum pluggen geplaats die bij het plaatsen van de 
contralaterale TKA weer werden verwijderd. Hierbij vonden zij ook geen verschil in 
botgroei snelheid tussen celecoxib (COX-2selectief) en geen NSAIDs. Ince et al. (37) 
lieten zien dat HO-profylaxe in de vorm van Radiotherapie (n=106), indomethacine 
(n=98) of  geen profylaxe (n=82) geen verschil in loslating van acetabulaire componenten 
geeft. Wurnig et al. (77) vonden ook geen verschil in loslating na 6 jaar tussen patiënten 
die indomethacine en patiënten die geen profylaxe hadden gehad. Het remmende 
effect van NSAIDs op bot ingroei lijkt dus beperkt te zijn.
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Vraag 4: Kunnen we de lokale inflammatoire respons na het plaatsen van 
een THA meten door de cytokines in drainvocht te bepalen?
De belangrijkste oorzaak voor het ontstaan van HO lijkt trauma en de inflammatoire 
reactie op dit trauma te zijn. Verschillende cytokines reguleren de inflammatoire 
respons na een trauma, waarbij een deel van de cytokines pro-inflammatoir werkt 
(met name IL1 1β, IL-6 en TNF-α). En een deel anti-inflammatoir (m.n IL-10). IL-6 
is tijdelijk verhoogd na electieve chirurgie (1, 23, 44, 48, 55, 66, 74, 78), maar ook na 
trauma (27). Naast een verhoging van de pro-inflammatoire cytokines na een trauma, 
kunnen ook de anti-inflammatoire (m.n IL-10) verhoogd zijn (27, 28). Een belangrijke 
bevinding is ook dat een verhoogde concentratie van IL-10 direct na een trauma is 
gecorreleerd met het optreden van een sepsis tijdens de behandeling (28). De IL-6/
IL-10 ratio kan gebruikt worden als maat voor de inflammatoire respons, waarbij 
een stijging van deze ratio een relatieve toename van de pro-inflammatoire cytokines 
laat zien (67). Omdat cytokines een belangrijke rol spelen in de communicatie tussen 
cellen (53), zou een concentratie van deze stoffen op lokaal niveau af  kunnen wijken 
van de meting die verricht worden in plasma. Er zijn echter maar weinig gegevens 
bekend over de lokale concentraties van cytokines in het operatiegebied (1, 36, 43, 
66, 75). Aangezien het vrijwel onmogelijk is om de lokale concentratie cytokines op 
interstitieel niveau te bepalen, hebben we de cytokines gemeten in drainvocht, waarbij 
we verwachten dat deze waarden meer een afspiegeling zijn van de gebeurtenissen 
op interstitieel niveau in vergelijking met de metingen die gedaan worden in plasma. 
Daarnaast is in de eerdere studies eigenlijk alleen naar de pro-inflammatoire cytokines 
gekeken.
In hoofdstuk 8 staat een pilot studie beschreven, waarin drainvocht werd verzameld na 1 
en 6 uur na het plaatsen van een THA. In dit drainvocht is een forse stijging te zien van 
vrijwel alle cytokines, maar een grotere stijging van de pro-inflammatoire. Daarnaast 
werd een stijging gezien van de IL-6/IL-10 ratio tussen de meting van 1 en 6 uur 
postoperatief, hetgeen suggestief  is dat er een verhoogde activiteit is van vooral de 
pro-inflammatoire cytokines. Aangezien het lokale protocol HO profylaxe voorschrijft 
na een THA, konden we de concentratie van deze cytokines helaas niet vergelijken 
met de waarden van patiënten die geen NSAIDs hadden gebruikt. Buvanendran (11) 
vergeleek cytokine concentraties in drainvocht (en liquor) en vond hogere concentratie 
van zowel interleukines als prostaglandines in patiënten die geen NSAIDs hadden 
gebruikt in vergelijking met patiënten die rofecoxib hadden gekregen. De waarden 
die in hoofdstuk 8 beschreven staan kunnen niet met deze studie vergeleken worden 
aangezien Buvanendran andere tijdsintervallen voor de bepalingen heeft gebruikt. In 
deze pilot studie bleek het dus mogelijk te zijn om de inflammatoire respons te meten 
in drainvocht, waarbij vooral de pro-inflammatoire cytokines verhoogd zijn na 6 uur. 
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Conclusies:
1 Drie dagen indomethacine als profylaxe voor HO is minder effectief  dan   
 indomethacine voor 7 dagen.
2 COX-2 selectieve NSAIDs hebben een vergelijkbaar profylactisch effect op HO  
 na THA in vergelijking met de klassieke NSAIDs. 
3 Het effect van NSAIDs op botingroei lijkt beperkt te zijn.
4 De inflammatoire respons na THA kan in het drainvocht worden gemeten,   
 hierbij zijn vooral de pro-inflammatoire cytokines verhoogd.
Afsluitende opmerkingen en suggesties voor toekomstig 
onderzoek
Heterotope ossificatie is een complicatie na THA die zonder het geven van profylaxe 
in ongeveer 50% van de patiënten voorkomt. Door profylactisch behandeling 
met NSAIDs kan de incidentie worden verminderd, waarbij de kortste effectieve 
behandelings periode 1 week lijkt te zijn. De resultaten van een profylactische 
behandeling met COX-2 selectieve middelen is vergelijkbaar met die van traditionele 
NSAIDs. De COX-2 selectieve middelen geven een verhoogd cardiovasculair risico 
als ze meer dan 18 maanden worden gebruikt, voor een korte behandelingsduur is dit 
verhoogde risico niet aangetoond. Echter deze relatief  nieuwe klasse van medicijnen 
is nog onvoldoende onderzocht bij postoperatief  gebruik.
Aangezien de data over het effect van NSAIDs op botingroei en fractuurgenezing 
tegenstrijdig zijn en het vanuit de klinische praktijk moeilijk is voor te stellen dat dit effect 
groot is, aangezien vrijwel alle traumapatiënten in de dagelijkse praktijk een NSAID 
krijgen en dit niet tot een klinisch probleem lijkt te leiden, is er meer onderzoek naar 
het effect van NSAIDs op bot ingroei en fractuurgenezing nodig. Voor een dergelijk 
onderzoek zouden patiënten vergeleken kunnen worden die wel en geen NSAIDs 
gebruiken. De meeste onderzoeken die deze twee groepen met elkaar vergelijken 
zijn meestal retrospectief  en hebben methodologische tekortkomingen. Vooral in 
retrospectieve studies hoeft het niet noodzakelijkerwijs te betekenen dat patiënten die 
geen NSAIDs voorgeschreven hebben gekregen ook geen NSAIDs hebben gebruikt, 
aangezien deze middelen ook zonder recept te verkrijgen zijn. Daarnaast wordt een 
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associatie gelegd tussen het gebruik van NSAIDs tussen de 60 en 90 dagen na een 
trauma en het ontstaan van een pseudarthrose (5). Hoewel hier sprake kan zijn van 
een causaal verband is het minstens zo aannemelijk om te redeneren dat patiënten 
met een pseudarthrose meer pijnstillers gebruiken. Veel voorkomende fracturen, 
bijvoorbeeld distale radius fracturen, zouden gerandomiseerd vergeleken kunnen 
worden tussen patiënten die NSAIDs krijgen en mensen die een placebo krijgen. 
Aangezien de consolidatie van een osteotomie ook nadelig beïnvloed zou kunnen 
worden door NSAIDs, zouden ook patiënten die een osteotomie ondergaan kunnen 
worden gerandomiseerd tussen NSAIDs of  placebo behandeling.
Aangezien de fixatie van ongecementeerde protheses ook afhankelijk is van de ingroei 
van het bot in de prothese zou dit ook een goede onderzoeksgroep kunnen zijn. 
Aangezien de standaard röntgenfoto voor de beoordeling van de fixatie onvoldoende 
is zouden we hier twee ander uitkomstmaten kunnen gebruiken. Allereerst het aantal 
revisies vergelijken tussen patiënten die wel en patiënten die geen NSAIDs gebruikt 
hebben. Aangezien het revisiepercentage rond de 10% na 10 jaar ligt, zullen we een 
groot cohort en een lange follow-up nodig hebben. 
Een andere mogelijkheid is om patiënten die wel en patiënten die geen NSAIDs 
krijgen na een ongecementeerde THA te vervolgen met RSA (Roentgen 
Stereophotogrammetric Analysis). Met deze gevalideerde methode is het mogelijk 
om loslating of  migratie van een prothese vroegtijdig op te sporen (38, 70, 71). Een 
voordeel van het gebruik van deze methode is dat er een kleinere groep patiënten en 
een kortere follow-up nodig zijn in vergelijking met een observationele studie waarbij 
de revisiepercentages vergeleken worden.
Om meer te weten te komen over het lokale inflammatoire proces, zouden cytokine 
concentraties in drainvocht vergeleken kunnen worden tussen patiënten die wel 
en patiënten die geen NSAIDs gebruiken. Aangezien de inflammatoire respons 
wisselt gedurende de tijd, zou het zinvol zijn om ook de cytokines op verschillende 
tijdsintervallen te bepalen.
Daarnaast zou het interessant zijn om een relatie tussen de verschillende cytokines en 
het al dan niet optreden van HO te onderzoeken. 
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onbewust geholpen, die wil ik dan ook oprecht bedanken. Hoewel het noemen van 
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Allereerst mijn promotor: professor van Kampen, beste Albert, je hebt me op weg 
geholpen bij mijn eerste schreden op het wetenschappelijke pad. Toen wisten we 
beiden niet dat het er ooit nog van zou komen, dat het een boekje zou worden. Toen 
ik vorig jaar bij je kwam met het voorstel om de onderzoeken te bundelen was je 
direct enthousiast en ik heb veel aan je gehad om het daadwerkelijk af  te ronden tot 
een proefschrift. Je enthousiasme voor de patiëntenzorg en de wetenschap zijn een 
belangrijke inspiratiebron voor me geweest.
Mijn copromotores: Dr B.W. Schreurs, beste Wim, Als een diesel hebben we het 
onderzoek verricht, het heeft al met al jaren geduurd, maar uiteindelijk is het af ! 
Als wetenschapper wist je me goed op weg te helpen met zowel de opzet als de 
uitvoering, en zeker ook met de afronding van de verschillende onderzoeken. Je snelle 
commentaar en bereikbaarheid bij deze verschillende fasen van het onderzoek heb ik 
zeer gewaardeerd en zijn een goede stimulans geweest. 
Dr W.J. Rijnberg, beste Willard, Ik heb mijn “Arnhemse tijd” als erg prettig ervaren. 
Goed dat ik van jullie de ruimte kreeg om twee klinische studies uit te voeren, die 
zowel voor de staf  als al het andere personeel erg belastend zijn geweest. Ook bij de 
afronding van zowel de twee artikelen waarvan je medeauteur bent als het manuscript 
heb ik veel aan je adviezen gehad.
Alle medeauteurs van de verschillende studies: Rinco Koorevaar, hoewel we nauwelijks 
tegelijkertijd in 1 kliniek hebben gewerkt, heb je wel aan de wieg gestaan van dit 
proefschrift. Het eerste artikel van ons samen is in 1999 gepubliceerd en is gebaseerd 
op een onderzoek dat we in 1996 opgestart hebben, van het laatste artikel is de inkt nog 
maar net droog. Albert Lemmens, dank voor je kritische maar leerzame commentaar, 
niet alleen voor deze studies, maar ook voor ons vak als geheel. Maarten Spruit, Rob 
Slappendel, Eric Weber en Jacques van Limbeek, dank voor jullie hulp met de twee 
artikelen die in de Sint Maartenskliniek zijn ontstaan. Helaas heeft Niels Klooster de 
afronding van mijn proefschrift niet meer mee kunnen maken.
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“Broeder”Gerjon Hannink, wat een lol hebben we gehad! Het was echt een feest 
om met jou de geiten te opereren en daarna talloze keren binnen te lopen voor weer 
wat adviezen voor de computer of  gewoon met een kop koffie praten over mijn 
“levensreddende handelingen”. Het is jammer dat er maar twee paranimfen naast me 
mogen staan…
Adriaan van Sorge, als ziekenhuisapotheker hoefde je eigenlijk alleen voor de pillen te 
zorgen, maar zowel bij de opzet als de uitvoering maar zeker ook bij het schrijven van 
het artikel heb ik veel aan je gehad.
Peter van der Kraan, dank voor je hulp bij de opzet en uitvoering van de drainvochtstudie, 
maar vooral bij de hulp bij het vertalen van al die getalletjes in een artikel. 
Hooggeleerde Buma, beste Pieter, dank voor je inbreng in de basaal wetenschappelijke 
artikelen. Toen je het botkamerverhaal helemaal om wilde gooien was ik niet zo 
enthousiast, maar gelukkig hebben we het wel gedaan. Het is inderdaad mooier zo!
Voor de vier klinische studies hebben heel mensen zich ingezet voor de inclusie van 
de patiënten, zonder ze bij naam te noemen wil ik alle collega’s nogmaals hartelijk 
danken voor al die mensen die jullie hebben geïncludeerd (in totaal waren dat er bijna 
500!).
Daarnaast een speciaal woord van dank voor de verpleging en secretaresses van B7V2 en 
de polimedewerkers van het Rijnstate ziekenhuis in Arnhem, jullie hebben belangeloos 
heel veel werk verricht met de Vioxx-studie en vooral met de drainvochtstudie. Zonder 
Elsbeth Mulder zou het niet mogelijk zijn geweest om op zo’n soepele manier 200 
patiënten voor nacontrole te zien op de dagen dat het mij uitkwam. 
De mensen van het dierenlab en de boerderij, hartelijk dank voor de assistentie bij de 
operaties, de gezelligheid, de koffie en als belangrijkste: bedankt voor de goede zorgen 
voor “mijn”geiten.
Léon Driesen, 27 geiten, 6 kamers per geit, 3 coupes per kamer en twee verschillende 
kleuringen per coupe…bijna 1000 histologische plaatjes…en die ook nog allemaal 
gedigitaliseerd, hartelijk dank!
Edward Valstar, Henri Timmers en Gerjon Hannink, hartelijk dank voor de kritische 
blik op het manuscript, waarbij veel zinsneden die aanvankelijk duidelijk leken nu 
veel beter leesbaar zijn geworden. Door jullie waardevolle taalkundige adviezen en 
correcties is ook het Engels van een veel betere kwaliteit geworden.
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Robert Gaasbeek, maatje tijdens een deel van de opleiding en zeker in het gezamenlijke 
jaar fellowship. Ik mis het heerlijke gezeur tussen de werkzaamheden door en de 
maandagavonden zijn niet meer zoals twee jaar geleden. Het is ons toch allebei gelukt 
om het boekje af  te krijgen. Ik vond het een eer dat ik vorig jaar naast jou mocht staan 
en ben erg blij dat je nu mij komt ondersteunen.
Zonder stimulans lukt het je ook niet om zo’n boekje te schrijven. Een aantal collega’s 
heeft me bewust of  onbewust herhaaldelijk gemotiveerd om het boekje af  te schrijven: 
Allard Hosman, Arthur van Noort, Bart Schreuder, Bart Swierstra, Corne van Loon, 
Denise Eygendaal, Job van Susante, Maarten de Waal Malefijt, Marinus de Kleuver, 
Mark Stegeman, Mirjam de Haart, Rene Veth en Ronald van Heerwaarden.
Het schrijven van een proefschrift gebeurt zeker niet alleen op het werk! De steun van 
de eigen sociale omgeving is daarbij van onschatbare waarde. Lieve Marie Christine 
Verbruggen, als buurvrouw en vriendin ben je van onschatbare waarde geweest voor 
mijn gehele carrière. 
Lieve Eric Dechnar, door dik en dun al meer dan 15 jaar goede maatjes. Altijd een 
luisterend oor als er weer eens wat tegenzat op het werk of  met het onderzoek of  privé. 
Ik ben erg blij dat je vandaag ook naast me staat.
Lieve Bin, dank voor je hulp bij de lay-out, het ontwerp van de kaft en om al je steun 
bij de “laatste lootjes”.  Ik ben erg blij dat je in mijn leven bent gekomen.
Lieve Ma, Mijn wetenschappelijk carrière begon al vroeg, al voor ik kon lopen ging 
ik vaak op onderzoek uit: abrikozenjam, talkpoeder, aardbeien en ga zo maar door. 
Ik heb van jullie altijd alle mogelijkheden gekregen om me verder te ontplooien ook 
als jullie het op dat moment niet altijd met mijn keuzes eens waren. Toen ik voor 
de tweede keer uitgeloot was, was Pa nog kwader dan ik over het oneerlijke van een 
loting. Helaas heeft hij niet meer mee mogen maken dat ik toch nog ben ingeloot, dat 
ik specialist ben geworden en dat ik ook mijn proefschrift heb geschreven. Wat zou hij 
trots geweest zijn op zijn kleine jongen! Uiteraard draag ik het proefschrift ook aan 
hem op.
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